## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2021-04-14_Virtual Town Hall 51_fixnames.md
last updated: 2025-01-03 Created QA Sections
link pdf: https://www.fda.gov/media/147771/download?attachment
link youtube: https://youtu.be/NM8edzTUIKE
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Updates on SARS-CoV-2 Test Authorizations

QA Block 1-1
CLARIFIED QUESTION: What distinguishes over-the-counter COVID-19 tests from those requiring a prescription?
CLARIFIED ANSWER: Over-the-counter COVID-19 tests, like the Lucira Check It, are intended for single-use at-home screening, whereas the same test was previously authorized only for use with a prescription.
VERBATIM QUESTION: What distinguishes over-the-counter COVID-19 tests from those requiring a prescription?
VERBATIM ANSWER: Last week we authorized the Lucira Check It COVID-19 tests for over-the-counter use for single use at-home screening tests. And this one was previously authorized for prescription home testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Over-the-counter vs prescription tests, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: What defines a reissue of a letter of authorization versus a revised EUA under the FDA's procedures?
CLARIFIED ANSWER: A 'reissue' involves changes to the letter of authorization, such as updating intended use or conditions, whereas a 'revised' EUA refers to granting letters used for updates requiring FDA concurrence, often for changes to labeling.
VERBATIM QUESTION: What defines a reissue of a letter of authorization versus a revised EUA under the FDA's procedures?
VERBATIM ANSWER: If it says that it is a reissue that means that we reissued the letter of authorization and that's generally used for updates that change any of the details in the letter of authorization including updating the intended use and the conditions of authorization, et cetera. And then revised generally means that we issued what we refer to as granting letters. So those are the letters that you'll see if you expand the little plus sign on the EUA list and that will be letters that we grant to update some details about the EUA. And those are generally used for updates that require FDA  concurrence such as changing to labeling or changes to labeling but they don't impact the letter of authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: reissue of authorization, revised EUA, FDA terminology
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: Under what circumstances does the FDA issue granting letters for EUAs?
CLARIFIED ANSWER: Granting letters are issued for updates to EUAs that require FDA concurrence, such as labeling changes, but do not affect the letter of authorization.
VERBATIM QUESTION: Under what circumstances does the FDA issue granting letters for EUAs?
VERBATIM ANSWER: Revised generally means that we issued what we refer to as granting letters. So those are the letters that you'll see if you expand the little plus sign on the EUA list and that will be letters that we grant to update some details about the EUA. And those are generally used for updates that require FDA concurrence such as changing to labeling or changes to labeling but they don't impact the letter of authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: granting letters, EUA updates, labeling changes
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What types of changes to test labeling require FDA concurrence?
CLARIFIED ANSWER: FDA concurrence is required for revised updates to labeling, which are issued through granting letters and involve changes to EUA details without impacting the letter of authorization.
VERBATIM QUESTION: What types of changes to test labeling require FDA concurrence?
VERBATIM ANSWER: Revised generally means that we issued what we refer to as granting letters. So those are the letters that you'll see if you expand the little plus sign on the EUA list and that will be letters that we grant to update some details about the EUA. And those are generally used for updates that require FDA  concurrence such as changing to labeling or changes to labeling but they don't impact the letter of authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA concurrence, Test labeling changes, EUA updates
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: How does the FDA categorize updates to EUAs that involve minor changes, such as fixing typos?
CLARIFIED ANSWER: The FDA classifies updates to EUAs involving minor changes, such as fixing typos or minor clarifications, as 'updated' in emails. These updates involve posting new labeling without reissuing the letter of authorization or issuing a granting letter.
VERBATIM QUESTION: How does the FDA categorize updates to EUAs that involve minor changes, such as fixing typos?
VERBATIM ANSWER: And then if the email says updated then that is referring to updates to labeling where we might have posted new labeling without issuing any letters. So without reissuing the letter of authorization and without issuing a granting letter. And that's usually used for minor changes to the labeling fixing typos, minor clarifications, things that are generally not substantive to the performance of the test or don't involve evaluation of new data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA updates, Minor changes, Labeling clarifications
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: What is the significance of adding reference panel result data to the test labeling according to the FDA?
CLARIFIED ANSWER: Adding reference panel results to test labeling provides updated information but does not typically involve reissuing or granting new letters of authorization.
VERBATIM QUESTION: What is the significance of adding reference panel result data to the test labeling according to the FDA?
VERBATIM ANSWER: And then we also use that updated labeling when we are adding results from the reference panel to the labeling of the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: reference panel results, test labeling updates, authorization letters
REVIEW FLAG: False


#### 2. Process for Removing EUA Tests from Market

QA Block 2-2
CLARIFIED QUESTION: Would a test developer be removed from the EUA page if they notify FDA about taking their EUA off the market?
CLARIFIED ANSWER: FDA asks test developers to notify them via email if they intend to take their EUA off the market. FDA will work with the developer, revoke the EUA upon request, and remove the developer from the EUA authorization list on the FDA website.
VERBATIM QUESTION: Would a test developer be removed from the EUA page if they notify FDA about taking their EUA off the market?
VERBATIM ANSWER: We do ask the test developer to inform FDA if they intend to take their EUA off the market. You can do that just by sending in an email to the CDRH EUA template's mailbox and we will respond to you and go through the process with you that way. Generally if you're planning to take a test off the market we will revoke the EUA. And the revocation will note that it was per your request and we would remove the test developer from the EUA authorization list on our Web site.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA revocation, FDA notification process, Test developer removal
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: What happens to the test listing on the EUA website if a developer voluntarily stops marketing their test?
CLARIFIED ANSWER: If a developer voluntarily stops marketing their test, the FDA will revoke the EUA, mark the revocation as requested by the developer, and remove the test from the EUA authorization list on the website. The test may be marked with an asterisk indicating it was voluntarily removed.
VERBATIM QUESTION: What happens to the test listing on the EUA website if a developer voluntarily stops marketing their test?
VERBATIM ANSWER: If you're planning to take a test off the market we will revoke the EUA. And the revocation will note that it was per your request and we would remove the test developer from the EUA authorization list on our Web site. Similarly if a developer has notified FDA through the policy in our guidance we would also ask that you let us know through an email to the template's box if you plan to stop marketing that test. And then we would generally remove you from the notification list and include - you can see on the removed list it includes an asterisk if their's was voluntarily.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA test removal, voluntary test marketing cessation
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Will the FAA notate on the removed list whether the withdrawal of a test was voluntary?
CLARIFIED ANSWER: FDA notes on the removed list with an asterisk if a test withdrawal was voluntary.
VERBATIM QUESTION: Will the FAA notate on the removed list whether the withdrawal of a test was voluntary?
VERBATIM ANSWER: And then we would generally remove you from the notification list and include - you can see on the removed list it includes an asterisk if their's was voluntarily.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA test withdrawal, voluntary withdrawal notation
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: Is there a specific email or mailbox to notify FDA about stopping marketing a test?
CLARIFIED ANSWER: Test developers should notify FDA about stopping marketing a test by sending an email to the CDRH EUA template's mailbox.
VERBATIM QUESTION: Is there a specific email or mailbox to notify FDA about stopping marketing a test?
VERBATIM ANSWER: You can do that just by sending in an email to the CDRH EUA template's mailbox and we will respond to you and go through the process with you that way. Similarly if a developer has notified FDA through the policy in our guidance we would also ask that you let us know through an email to the template's box if you plan to stop marketing that test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA revocation, FDA notification email
REVIEW FLAG: False


#### 3. Transition Plan for EUA Devices and Regulatory Pathways

QA Block 3-2
CLARIFIED QUESTION: What is the timeline for transitioning from EUAs to 510(k)s or De Novos for COVID-19 diagnostics?
CLARIFIED ANSWER: FDA cannot specify a timeline for transitioning from EUAs to 510(k)s or De Novos but is working on a transition plan, which is listed as FY21 priority guidance. EUAs remain active until the public health emergency ends, which historically is not accelerated. A first test was authorized for marketing outside the emergency (BioFire De Novo), opening the 510(k) route for other tests, but no immediate changes to EUAs are planned.
VERBATIM QUESTION: What is the timeline for transitioning from EUAs to 510(k)s or De Novos for COVID-19 diagnostics?
VERBATIM ANSWER: Next we have a question about the process and timing to discontinue EUAs and require 510k's or Denovos. And we have discussed this a little bit previously on calls. And we've mentioned before that I can't comment on a timeline specifically but we are working on a transition plan for devices that are offered under EUA. And this is included as a guidance document on the center's guidance priority list for FY21. If you take a look there you'll see the transition plan for medical devices distributed under enforcement policies or emergency's authorization during the COVID-19 public health emergency. Additionally it's important to recognize that generally unless they're revoked an EUA is in effect until the public health emergency is terminated. And the termination of a public health emergency does not typically happen on a particularly accelerated timeline. You can see that there are previous public health emergencies, like, Zika and Ebola that still have not been terminated. Now we have authorized the first test for marketing beyond the public health emergency with the BioFire Denovo. And that does open up the 510k pathway for other molecular diagnostic SARS-CoV-2 tests both individual or a single analyte SARS-CoV-2 test as well as multi-analyte panels which the Bio Fire test is. But that Denovo does not impact any other EUAs other than the BioFire EUA for that same identical test which was revoked concurrent to granting the Denovo. BioFire's other EUAs and other developer's EUAs were not impacted. So we can't anticipate when the public health emergency would end but we are working on that transition plan and we are committed to, you know,  ensuring that the public has access to a wide variety of test options for COVID-19 and we have no intention at the moment of stopping review for EUAs or revoking based solely on timeline or anything, like, that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA transition timeline, 510(k) and De Novo pathways, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Where can developers access the guidance document that outlines the transition plan for devices under EUA?
CLARIFIED ANSWER: Developers can access the guidance document outlining the transition plan for devices under EUA on the center's guidance priority list for FY21.
VERBATIM QUESTION: Where can developers access the guidance document that outlines the transition plan for devices under EUA?
VERBATIM ANSWER: We are working on a transition plan for devices that are offered under EUA. And this is included as a guidance document on the center's guidance priority list for FY21. If you take a look there you'll see the transition plan for medical devices distributed under enforcement policies or emergency's authorization during the COVID-19 public health emergency.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Transition plan for EUA devices, Guidance document location
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: What are the implications of the BioFire De Novo authorization for developers of other SARS-CoV-2 tests?
CLARIFIED ANSWER: The BioFire De Novo authorization opens up the 510k pathway for other SARS-CoV-2 molecular diagnostic tests, including single analyte and multi-analyte panels, without affecting existing EUAs other than the BioFire EUA for the identical test which was revoked.
VERBATIM QUESTION: What are the implications of the BioFire De Novo authorization for developers of other SARS-CoV-2 tests?
VERBATIM ANSWER: Now we have authorized the first test for marketing beyond the public health emergency with the BioFire Denovo. And that does open up the 510k pathway for other molecular diagnostic SARS-CoV-2 tests both individual or a single analyte SARS-CoV-2 test as well as multi-analyte panels which the Bio Fire test is. But that Denovo does not impact any other EUAs other than the BioFire EUA for that same identical test which was revoked concurrent to granting the Denovo. BioFire's other EUAs and other developer's EUAs were not impacted.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: BioFire De Novo authorization, 510k pathway, Impact on EUAs
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: Does the authorization of a De Novo test affect EUAs for molecular diagnostic tests by other developers?
CLARIFIED ANSWER: The authorization of a De Novo test, such as BioFire, does not affect EUAs for molecular diagnostic tests by other developers, except for the identical BioFire EUA that was revoked when the De Novo was granted.
VERBATIM QUESTION: Does the authorization of a De Novo test affect EUAs for molecular diagnostic tests by other developers?
VERBATIM ANSWER: But that Denovo does not impact any other EUAs other than the BioFire EUA for that same identical test which was revoked concurrent to granting the Denovo. BioFire's other EUAs and other developer's EUAs were not impacted.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: De Novo test authorization, Impact on EUAs, Molecular diagnostic tests
REVIEW FLAG: False

QA Block 3-7
CLARIFIED QUESTION: What is the FDA's approach to managing EUAs as the public health emergency continues indefinitely?
CLARIFIED ANSWER: The FDA is working on a transition plan for devices under EUA, which is included in the guidance priority list for FY21. EUAs remain valid until the public health emergency is terminated. While the FDA cannot anticipate an end to the public health emergency, they are ensuring availability of test options and do not plan to stop EUA reviews or revoke authorizations based on timelines.
VERBATIM QUESTION: What is the FDA's approach to managing EUAs as the public health emergency continues indefinitely?
VERBATIM ANSWER: I can't comment on a timeline specifically but we are working on a transition plan for devices that are offered under EUA. And this is included as a guidance document on the center's guidance priority list for FY21. If you take a look there you'll see the transition plan for medical devices distributed under enforcement policies or emergency's authorization during the COVID-19 public health emergency. Additionally it's important to recognize that generally unless they're revoked an EUA is in effect until the public health emergency is terminated. And the termination of a public health emergency does not typically happen on a particularly accelerated timeline. You can see that there are previous public health emergencies, like, Zika and Ebola that still have not been terminated. Now we have authorized the first test for marketing beyond the public health emergency with the BioFire Denovo. And that does open up the 510k pathway for other molecular diagnostic SARS-CoV-2 tests both individual or a single analyte SARS-CoV-2 test as well as multi-analyte panels which the Bio Fire test is. But that Denovo does not impact any other EUAs other than the BioFire EUA for that same identical test which was revoked concurrent to granting the Denovo. BioFire's other EUAs and other developer's EUAs were not impacted. So we can't anticipate when the public health emergency would end but we are working on that transition plan and we are committed to, you know,  ensuring that the public has access to a wide variety of test options for COVID-19 and we have no intention at the moment of stopping review for EUAs or revoking based solely on timeline or anything, like, that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA transition plan, Public health emergency, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 3-8
CLARIFIED QUESTION: Does the FDA plan to stop reviewing EUAs based solely on timeline considerations?
CLARIFIED ANSWER: The FDA does not currently plan to stop reviewing EUAs or revoke them based solely on timeline considerations.
VERBATIM QUESTION: Does the FDA plan to stop reviewing EUAs based solely on timeline considerations?
VERBATIM ANSWER: we have no intention at the moment of stopping review for EUAs or revoking based solely on timeline or anything, like, that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUAs, Timeline considerations, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 3-9
CLARIFIED QUESTION: Can developers still submit EUAs for COVID-19 diagnostic tests despite ongoing transition planning?
CLARIFIED ANSWER: The FDA is continuing to review EUAs for COVID-19 diagnostic tests and does not plan to stop based solely on timelines, even during the transition planning process.
VERBATIM QUESTION: Can developers still submit EUAs for COVID-19 diagnostic tests despite ongoing transition planning?
VERBATIM ANSWER: We are working on that transition plan and we are committed to, you know, ensuring that the public has access to a wide variety of test options for COVID-19 and we have no intention at the moment of stopping review for EUAs or revoking based solely on timeline or anything, like, that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submissions, COVID-19 diagnostic tests, Transition planning
REVIEW FLAG: False


#### 4. Guidance for Home Collection Kits and Testing Compliance

QA Block 4-1
CLARIFIED QUESTION: Would the FDA accept an EUA request with a general description of the process for shipping and specimen handling, leaving specific logistics to be established by each laboratory or by the collection kit manufacturer?
CLARIFIED ANSWER: The FDA generally allows and considers EUA requests for home collection kits intended for use by multiple lab partners, provided an accessioning protocol is submitted. This protocol should outline shipping and sample stability, pre-acceptance lab procedures, consistent kit instructions across labs, and product purchaser checks. FDA is open to further discussions regarding submission details.
VERBATIM QUESTION: Would the FDA accept an EUA request with a general description of the process for shipping and specimen handling, leaving specific logistics to be established by each laboratory or by the collection kit manufacturer?
VERBATIM ANSWER: Generally we do allow the submission of and we would consider submission of an EUA request for a home collection kit with the intent of it being used by multiple lab partners. We would recommend that you develop and submit an accessioning protocol that includes information about how long the shipping stabilities support, the sample stability rather. And the procedures that a lab should perform before accepting a sample for testing. We would want to see that you've built in assurances that all the labs would use the same home collection kit instructions with, you know, minor edits for programs that we do through labeling review. And that there will be assurances for checking that purchasers of the product are using the appropriate assay supported by the collection kit. And we are happy to have further discussions in the context of your particular submission on those details.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission process, Home collection kits, Specimen handling
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Can an at-home test be performed in a public setting such as a college, school, or workplace instead of strictly in a home?
CLARIFIED ANSWER: According to FDA, at-home tests can be used for self-testing in non-home settings, such as colleges, schools, or workplaces. However, if someone else at the facility conducts the test, the facility would typically need a CLIA waiver.
VERBATIM QUESTION: Can an at-home test be performed in a public setting such as a college, school, or workplace instead of strictly in a home?
VERBATIM ANSWER: So this one is really a question for CLIA. So we would recommend that you reach out to CLIA for a definitive answer. But our understanding is that an at-home test can be used for self-testing in a non-home setting. But if the test is performed by someone else at the facility then the facility would need to have a CLIA certificate which would generally be a certificate of waiver in that situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: at-home testing in non-home settings, CLIA requirements
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: If an at-home test is performed in a public setting by the facility rather than the individual, are such tests exempt from CLIA regulations?
CLARIFIED ANSWER: The FDA recommends contacting CLIA for a definitive answer. Their understanding is that at-home tests can be used for self-testing in public settings like schools or workplaces, but if the facility performs the test, a CLIA certificate (likely a waiver) is required.
VERBATIM QUESTION: If an at-home test is performed in a public setting by the facility rather than the individual, are such tests exempt from CLIA regulations?
VERBATIM ANSWER: So this one is really a question for CLIA. So we would recommend that you reach out to CLIA for a definitive answer. But our understanding is that an at-home test can be used for self-testing in a non-home setting. But if the test is performed by someone else at the facility then the facility would need to have a CLIA certificate which would generally be a certificate of waiver in that situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: at-home tests in public settings, CLIA regulations, self vs facility-performed testing
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: What specific details should be included in an accessioning protocol for a home collection kit to support an EUA submission?
CLARIFIED ANSWER: The FDA recommends including details on shipping and sample stability, as well as lab procedures for sample acceptance in an accessioning protocol. It should also ensure consistent use of home collection kit instructions and verification that users employ the correct assay.
VERBATIM QUESTION: What specific details should be included in an accessioning protocol for a home collection kit to support an EUA submission?
VERBATIM ANSWER: We would recommend that you develop and submit an accessioning protocol that includes information about how long the shipping stabilities support, the sample stability rather. And the procedures that a lab should perform before accepting a sample for testing. We would want to see that you've built in assurances that all the labs would use the same home collection kit instructions with, you know, minor edits for programs that we do through labeling review. And that there will be assurances for checking that purchasers of the product are using the appropriate assay supported by the collection kit.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission, Home collection kit, Accessioning protocol
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: What level of consistency is expected across multiple laboratories using the same home collection kit, particularly in terms of using identical instructions?
CLARIFIED ANSWER: The FDA expects consistency among labs using the same home collection kit by ensuring all labs utilize identical instructions, with only minor edits permitted through labeling review.
VERBATIM QUESTION: What level of consistency is expected across multiple laboratories using the same home collection kit, particularly in terms of using identical instructions?
VERBATIM ANSWER: We would want to see that you've built in assurances that all the labs would use the same home collection kit instructions with, you know, minor edits for programs that we do through labeling review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: home collection kits, laboratory consistency, labeling review
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: How should developers ensure that purchasers of collection kits are using the correct assay associated with the kit?
CLARIFIED ANSWER: FDA advises developers to ensure labs use consistent home collection kit instructions and implement measures to verify purchasers are using the correct assay associated with the kit.
VERBATIM QUESTION: How should developers ensure that purchasers of collection kits are using the correct assay associated with the kit?
VERBATIM ANSWER: We would want to see that you've built in assurances that all the labs would use the same home collection kit instructions with, you know, minor edits for programs that we do through labeling review. And that there will be assurances for checking that purchasers of the product are using the appropriate assay supported by the collection kit.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: collection kits, assay usage, developer guidelines
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: What are the FDA's expectations regarding minor edits to home collection kit labeling made for specific programs?
CLARIFIED ANSWER: The FDA expects all labs to use consistent home collection kit instructions, allowing only minor edits for specific programs as reviewed through labeling.
VERBATIM QUESTION: What are the FDA's expectations regarding minor edits to home collection kit labeling made for specific programs?
VERBATIM ANSWER: We would want to see that you've built in assurances that all the labs would use the same home collection kit instructions with, you know, minor edits for programs that we do through labeling review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: home collection kit labeling, FDA labeling review, minor labeling edits
REVIEW FLAG: False

QA Block 4-8
CLARIFIED QUESTION: What assurances are needed to confirm that sample shipping and stability are adequately addressed in an EUA request for a home collection kit?
CLARIFIED ANSWER: The FDA recommends submitting an accessioning protocol detailing shipping and sample stability, lab procedures for sample acceptance, standardized instructions for all labs with minor labeling edits, and assurance mechanisms verifying appropriate assay usage with the collection kit.
VERBATIM QUESTION: What assurances are needed to confirm that sample shipping and stability are adequately addressed in an EUA request for a home collection kit?
VERBATIM ANSWER: We would recommend that you develop and submit an accessioning protocol that includes information about how long the shipping stabilities support, the sample stability rather. And the procedures that a lab should perform before accepting a sample for testing. We would want to see that you've built in assurances that all the labs would use the same home collection kit instructions with, you know, minor edits for programs that we do through labeling review. And that there will be assurances for checking that purchasers of the product are using the appropriate assay supported by the collection kit.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA requirements for sample stability, Accessioning protocol, Standardized lab procedures
REVIEW FLAG: False

QA Block 4-9
CLARIFIED QUESTION: In what scenarios would a CLIA waiver be required for a facility using an at-home test?
CLARIFIED ANSWER: FDA understands that an at-home test can be used for self-testing in non-home settings, but if performed by someone else at the facility, a CLIA certificate (generally a waiver) is needed.
VERBATIM QUESTION: In what scenarios would a CLIA waiver be required for a facility using an at-home test?
VERBATIM ANSWER: So this one is really a question for CLIA. So we would recommend that you reach out to CLIA for a definitive answer. But our understanding is that an at-home test can be used for self-testing in a non-home setting. But if the test is performed by someone else at the facility then the facility would need to have a CLIA certificate which would generally be a certificate of waiver in that situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA waiver, At-home tests, Facility testing requirements
REVIEW FLAG: False


#### 5. Validation of Multi-Analyte Antigen Tests Using Contrived Samples

QA Block 5-1
CLARIFIED QUESTION: Can multi-analyte antigen tests leverage contrived samples for the initial authorization with a closed authorization commitment?
CLARIFIED ANSWER: FDA generally does not accept the use of contrived samples for the initial authorization of multi-analyte antigen tests. A prospective study is preferred, using an FDA-authorized RT-PCR comparator for CoV-2 and an FDA-cleared comparator for other analytes. If archived specimens cannot be used due to technological limitations, FDA recommends submitting a pre-EUA for guidance.
VERBATIM QUESTION: Can multi-analyte antigen tests leverage contrived samples for the initial authorization with a closed authorization commitment?
VERBATIM ANSWER: And generally we would not consider it to be acceptable to use contrived samples for initial authorization of a multi-analyte test. We would want to see a prospective study to support the EUA request that includes an FDA authorized RT-PCR for the comparator for CoV-2 and an FDA cleared comparator for all the other claimed analytes. And if there are technological considerations that preclude the use of archived specimens such as what was mentioned in this question as the sample type not surviving the archival process. And we would encourage you to submit a pre-EUA to discuss the next steps for your specific situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: multi-analyte antigen tests, authorization requirements, use of contrived samples
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: What are the validation requirements for multi-analyte antigen tests if the sample types used do not survive the archival process?
CLARIFIED ANSWER: FDA generally does not accept using contrived samples for initial authorization of multi-analyte antigen tests. Instead, they require a prospective study with an FDA-authorized RT-PCR as the comparator for CoV-2 and FDA-cleared comparators for other claimed analytes. If archived specimens cannot be used due to technical reasons, FDA recommends submitting a pre-EUA to discuss next steps.
VERBATIM QUESTION: What are the validation requirements for multi-analyte antigen tests if the sample types used do not survive the archival process?
VERBATIM ANSWER: And generally we would not consider it to be acceptable to use contrived samples for initial authorization of a multi-analyte test. We would want to see a prospective study to support the EUA request that includes an FDA authorized RT-PCR for the comparator for CoV-2 and an FDA cleared comparator for all the other claimed analytes. And if there are technological considerations that preclude the use of archived specimens such as what was mentioned in this question as the sample type not surviving the archival process. And we would encourage you to submit a pre-EUA to discuss the next steps for your specific situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Multi-analyte antigen test validation, EUA prospective study requirements, Use of contrived versus archived samples
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What steps should be taken if technological considerations preclude the use of archived specimens for multi-analyte antigen tests?
CLARIFIED ANSWER: If archived specimens cannot be used due to technological reasons, the FDA discourages contrived samples for initial authorization and advises a prospective study using specific comparators. Submit a pre-EUA to address individual circumstances.
VERBATIM QUESTION: What steps should be taken if technological considerations preclude the use of archived specimens for multi-analyte antigen tests?
VERBATIM ANSWER: Generally we would not consider it to be acceptable to use contrived samples for initial authorization of a multi-analyte test. We would want to see a prospective study to support the EUA request that includes an FDA authorized RT-PCR for the comparator for CoV-2 and an FDA cleared comparator for all the other claimed analytes. And if there are technological considerations that preclude the use of archived specimens such as what was mentioned in this question as the sample type not surviving the archival process. And we would encourage you to submit a pre-EUA to discuss the next steps for your specific situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: multi-analyte antigen test validation, technological limitations, pre-EUA submission
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: What is the FDA's expectation for a comparator test when conducting a prospective study for a multi-analyte antigen test?
CLARIFIED ANSWER: The FDA expects a prospective study for EUA submission to include an FDA-authorized RT-PCR for COVID-19 as the comparator and an FDA-cleared comparator for all other analytes in the test.
VERBATIM QUESTION: What is the FDA's expectation for a comparator test when conducting a prospective study for a multi-analyte antigen test?
VERBATIM ANSWER: We would want to see a prospective study to support the EUA request that includes an FDA authorized RT-PCR for the comparator for CoV-2 and an FDA cleared comparator for all the other claimed analytes.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Multi-analyte antigen test validation, FDA comparator expectations, Prospective studies
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: What alternative approaches are acceptable if archived specimens cannot be used for validation due to technological limitations?
CLARIFIED ANSWER: The FDA generally does not accept contrived samples for the initial authorization of multi-analyte tests. They require a prospective study with an FDA-authorized RT-PCR comparator for CoV-2 and FDA-cleared comparators for other analytes. For technological limitations with archived specimens, they recommend submitting a pre-EUA for further discussion.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: And generally we would not consider it to be acceptable to use contrived samples for initial authorization of a multi-analyte test. We would want to see a prospective study to support the EUA request that includes an FDA authorized RT-PCR for the comparator for CoV-2 and an FDA cleared comparator for all the other claimed analytes. And if there are technological considerations that preclude the use of archived specimens such as what was mentioned in this question as the sample type not surviving the archival process. And we would encourage you to submit a pre-EUA to discuss the next steps for your specific situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Validation of multi-analyte antigen tests, Use of archived vs. contrived samples, FDA authorization process
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: Is a pre-EUA necessary to address specific technological issues with sample stability for validation?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA if there are technological issues, such as sample type instability, to discuss next steps.
VERBATIM QUESTION: Is a pre-EUA necessary to address specific technological issues with sample stability for validation?
VERBATIM ANSWER: And if there are technological considerations that preclude the use of archived specimens such as what was mentioned in this question as the sample type not surviving the archival process. And we would encourage you to submit a pre-EUA to discuss the next steps for your specific situation.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pre-EUA process, technological issues, sample stability
REVIEW FLAG: False


#### 6. Review Priorities for SARS-CoV-2 Pre-Submissions

QA Block 6-2
CLARIFIED QUESTION: Does the prioritization for pre-submissions extend to a SARS-CoV-2 assay without an existing EUA authorization?
CLARIFIED ANSWER: FDA reviews SARS-CoV-2 pre-submissions to address public health needs, with prioritization based on public health priorities and specific details of the device.
VERBATIM QUESTION: Does the prioritization for pre-submissions extend to a SARS-CoV-2 assay without an existing EUA authorization?
VERBATIM ANSWER: So generally we are broadly committed to ensuring that the public has access to a wide variety of test options for COVID-19 and we do intend to continue to review SARS-CoV-2 pre-submissions to address public health needs. So to some extent - so COVID-19 related pre-submissions are one of the categories of pre-submissions that we do continue to review. And the review of those would be prioritized based on the public health needs. So we would still consider the particulars about the device in question as to whether it would be a priority with you.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SARS-CoV-2 assay pre-submissions, EUA authorization, Review prioritization
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: What factors does the FDA consider when determining the priority of reviewing SARS-CoV-2 related pre-submissions?
CLARIFIED ANSWER: The FDA prioritizes SARS-CoV-2 pre-submissions based on public health needs and the specific details of the device in question.
VERBATIM QUESTION: What factors does the FDA consider when determining the priority of reviewing SARS-CoV-2 related pre-submissions?
VERBATIM ANSWER: So generally we are broadly committed to ensuring that the public has access to a wide variety of test options for COVID-19 and we do intend to continue to review SARS-CoV-2 pre-submissions to address public health needs. So to some extent - so COVID-19 related pre-submissions are one of the categories of pre-submissions that we do continue to review. And the review of those would be prioritized based on the public health needs. So we would still consider the particulars about the device in question as to whether it would be a priority with you.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SARS-CoV-2 pre-submissions, FDA review priorities, Public health needs
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: Does the FDA intend to continue reviewing SARS-CoV-2 pre-submissions despite delays in other review categories?
CLARIFIED ANSWER: The FDA intends to continue reviewing SARS-CoV-2 pre-submissions, prioritizing them based on public health needs.
VERBATIM QUESTION: Does the FDA intend to continue reviewing SARS-CoV-2 pre-submissions despite delays in other review categories?
VERBATIM ANSWER: So generally we are broadly committed to ensuring that the public has access to a wide variety of test options for COVID-19 and we do intend to continue to review SARS-CoV-2 pre-submissions to address public health needs. So to some extent - so COVID-19 related pre-submissions are one of the categories of pre-submissions that we do continue to review. And the review of those would be prioritized based on the public health needs.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SARS-CoV-2 pre-submissions, review priorities, public health needs
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Are there specific criteria for prioritizing COVID-19 related pre-submissions based on public health needs?
CLARIFIED ANSWER: The FDA prioritizes reviewing COVID-19 related pre-submissions based on public health needs, while also considering the specifics of the device in question.
VERBATIM QUESTION: Are there specific criteria for prioritizing COVID-19 related pre-submissions based on public health needs?
VERBATIM ANSWER: So generally we are broadly committed to ensuring that the public has access to a wide variety of test options for COVID-19 and we do intend to continue to review SARS-CoV-2 pre-submissions to address public health needs. So to some extent - so COVID-19 related pre-submissions are one of the categories of pre-submissions that we do continue to review. And the review of those would be prioritized based on the public health needs. So we would still consider the particulars about the device in question as to whether it would be a priority with you.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID-19 diagnostics, Pre-submission prioritization, Public health needs
REVIEW FLAG: False


#### 7. Prioritization of Rapid Antigen Test EUA Submissions

QA Block 7-1
CLARIFIED QUESTION: Do you continue to review submissions for professional use rapid antigen tests with point of care settings with a CLIA certificate of waiver?
CLARIFIED ANSWER: The FDA continues to review submissions for rapid antigen tests for professional use in point-of-care settings with CLIA waivers, prioritizing tests that improve accessibility, reduce reliance on supplies, or have high throughput. Validation for home use is generally required for home tests.
VERBATIM QUESTION: Do you continue to review submissions for professional use rapid antigen tests with point of care settings with a CLIA certificate of waiver?
VERBATIM ANSWER: We do have many factors that go into our prioritization decision. And unfortunately not all of those factors are able to be made publicly evidenced since they do often consider other submissions that are in house. But we have previously stated that we're prioritizing review of EUA requests for tests that increase testing accessibility which includes point of care, home collection, at- home tests for example. Or that would significantly increase the testing capacity by reducing reliance on test supplies or tests that have high throughput and are widely distributed to address public health needs. And, you know, in this case if it is a test that is designed for home use we would generally want to see that it is validated for home use. We are still reviewing point of care tests as well. But, you know, depending on how the test is designed and what it is intended for we would want to have further discussions about that. So if you have questions about a decision about your test in particular please reach out.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Rapid antigen tests, Submissions review, Point-of-care settings
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: Would submissions without data for self-testing in a home use setting be considered low priority?
CLARIFIED ANSWER: The FDA prioritizes EUA reviews for tests that increase testing accessibility, such as point of care, home collection, or at-home tests, and those addressing public health needs. Validation for home use is necessary for home use tests, but the FDA still reviews point-of-care tests depending on their design and intended use.
VERBATIM QUESTION: Would submissions without data for self-testing in a home use setting be considered low priority?
VERBATIM ANSWER: So we do have many factors that go into our prioritization decision. And unfortunately not all of those factors are able to be made publicly evidenced since they do often consider other submissions that are in house. But we have previously stated that we're prioritizing review of EUA requests for tests that increase testing accessibility which includes point of care, home collection, at- home tests for example. Or that would significantly increase the testing capacity by reducing reliance on test supplies or tests that have high throughput and are widely distributed to address public health needs. And, you know, in this case if it is a test that is designed for home use we would generally want to see that it is validated for home use. We are still reviewing point of care tests as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Review prioritization, Home use validation, Point of care tests
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: Are you still reviewing point of care tests?
CLARIFIED ANSWER: FDA is still reviewing point of care tests, but the design and intended use of the test may require additional discussions.
VERBATIM QUESTION: Are you still reviewing point of care tests?
VERBATIM ANSWER: We are still reviewing point of care tests as well. But, you know, depending on how the test is designed and what it is intended for we would want to have further discussions about that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: point of care tests, FDA review priorities
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: What factors does the FDA consider when deciding EUA review priorities for COVID-19 tests?
CLARIFIED ANSWER: The FDA prioritizes tests that increase accessibility, such as point-of-care or at-home tests, and those that enhance testing capacity by reducing reliance on supplies or offering high throughput and widespread distribution. Some factors are not publicly available.
VERBATIM QUESTION: What factors does the FDA consider when deciding EUA review priorities for COVID-19 tests?
VERBATIM ANSWER: We do have many factors that go into our prioritization decision. And unfortunately not all of those factors are able to be made publicly evidenced since they do often consider other submissions that are in house. But we have previously stated that we're prioritizing review of EUA requests for tests that increase testing accessibility which includes point of care, home collection, at-home tests for example. Or that would significantly increase the testing capacity by reducing reliance on test supplies or tests that have high throughput and are widely distributed to address public health needs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA review factors, COVID-19 test prioritization, FDA testing criteria
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: Will tests that reduce reliance on limited test supplies or increase throughput receive higher prioritization?
CLARIFIED ANSWER: The FDA prioritizes EUA reviews for tests that increase accessibility, reduce reliance on limited test supplies, or have high throughput to address public health needs.
VERBATIM QUESTION: Will tests that reduce reliance on limited test supplies or increase throughput receive higher prioritization?
VERBATIM ANSWER: But we have previously stated that we're prioritizing review of EUA requests for tests that increase testing accessibility which includes point of care, home collection, at- home tests for example. Or that would significantly increase the testing capacity by reducing reliance on test supplies or tests that have high throughput and are widely distributed to address public health needs.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA prioritization criteria, Testing supply limitations, High-throughput tests
REVIEW FLAG: False

QA Block 7-7
CLARIFIED QUESTION: Does the FDA require tests intended for home use to be validated in that specific setting?
CLARIFIED ANSWER: Yes, the FDA generally requires tests intended for home use to be validated in that specific setting.
VERBATIM QUESTION: Does the FDA require tests intended for home use to be validated in that specific setting?
VERBATIM ANSWER: If it is a test that is designed for home use we would generally want to see that it is validated for home use.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: home use test validation, FDA test requirements
REVIEW FLAG: False

QA Block 7-8
CLARIFIED QUESTION: How does the intended use of a test affect FDA's review prioritization?
CLARIFIED ANSWER: FDA prioritizes EUA requests for tests that enhance testing accessibility, such as point of care, home collection, or at-home tests, or that significantly increase testing capacity. Additionally, tests designed for home use need proper validation.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We do have many factors that go into our prioritization decision. And unfortunately not all of those factors are able to be made publicly evidenced since they do often consider other submissions that are in house. But we have previously stated that we're prioritizing review of EUA requests for tests that increase testing accessibility which includes point of care, home collection, at-home tests for example. Or that would significantly increase the testing capacity by reducing reliance on test supplies or tests that have high throughput and are widely distributed to address public health needs. And, you know, in this case if it is a test that is designed for home use we would generally want to see that it is validated for home use. We are still reviewing point of care tests as well. But, you know, depending on how the test is designed and what it is intended for we would want to have further discussions about that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Review prioritization, Test intended use, EUA requests
REVIEW FLAG: False

QA Block 7-9
CLARIFIED QUESTION: Can developers discuss the specific prioritization decisions regarding their test directly with the FDA?
CLARIFIED ANSWER: Developers with specific questions about prioritization decisions regarding their test should contact the FDA directly.
VERBATIM QUESTION: Can developers discuss the specific prioritization decisions regarding their test directly with the FDA?
VERBATIM ANSWER: So if you have questions about a decision about your test in particular please reach out.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: test prioritization, developer-FDA communication
REVIEW FLAG: False


#### 8. Designing Clinical Trials for Asymptomatic Positive Enrichment

QA Block 8-1
CLARIFIED QUESTION: Is it acceptable to recruit asymptomatic subjects with recent positive test results if an equal number of asymptomatic subjects with recent negative test results are also recruited for a clinical trial design to enrich for asymptomatic positives for a nucleic acid test with a lateral flow readout?
CLARIFIED ANSWER: The FDA considers the proposed approach in the question generally acceptable, provided that the comparator method is used to enrich the clinical study population. For additional clarification or to refine the design, a pre-EUA consultation is recommended.
VERBATIM QUESTION: Is it acceptable to recruit asymptomatic subjects with recent positive test results if an equal number of asymptomatic subjects with recent negative test results are also recruited for a clinical trial design to enrich for asymptomatic positives for a nucleic acid test with a lateral flow readout?
VERBATIM ANSWER: So generally there are a variety of ways to enrich this clinical study. The proposal in this question generally appears acceptable. We would want to make sure that you are using the comparator method as the result that you're using to enrich your clinical study population. And if you have further questions or want to talk through the design you can reach out with a pre-EUA to discuss that study design as well.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical trial design, asymptomatic testing, pre-EUA consultation
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: Should a clinical trial design for a nucleic acid test use a comparator method as the result for enriching the clinical study population?
CLARIFIED ANSWER: FDA requires the use of a comparator method to enrich the clinical study population and recommends contacting through a pre-EUA for further design discussion.
VERBATIM QUESTION: Should a clinical trial design for a nucleic acid test use a comparator method as the result for enriching the clinical study population?
VERBATIM ANSWER: We would want to make sure that you are using the comparator method as the result that you're using to enrich your clinical study population. And if you have further questions or want to talk through the design you can reach out with a pre-EUA to discuss that study design as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical trial design, comparator method, nucleic acid tests
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: Can further questions regarding the clinical trial design be addressed through a pre-EUA request?
CLARIFIED ANSWER: FDA recommends reaching out through a pre-EUA request to discuss further questions about the clinical trial design.
VERBATIM QUESTION: Can further questions regarding the clinical trial design be addressed through a pre-EUA request?
VERBATIM ANSWER: If you have further questions or want to talk through the design you can reach out with a pre-EUA to discuss that study design as well. Kris did you want to add anything about that one about the study design or just to come in with a pre-EUA?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical trial design, pre-EUA requests
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: What other patient factors or risk factors could be considered to further mix populations in a clinical trial to enrich for asymptomatic positives?
CLARIFIED ANSWER: Other patient and risk factors, such as exposure scenarios, could be considered to mix populations in clinical trials. FDA recommends a pre-EUA submission to address nuances in design.
VERBATIM QUESTION: What other patient factors or risk factors could be considered to further mix populations in a clinical trial to enrich for asymptomatic positives?
VERBATIM ANSWER: Yes I think a pre-EUA probably is the right method because there are, you know, I think nuances to this approach. You know you could also consider, you know, other patient factors, risk factors where folks may be exposed to kind of further mix populations. There's a number of ways to do this.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Patient factors, Risk factors, Clinical trial enrichment
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: What nuances should be considered when evaluating a clinical trial design for nucleic acid tests with a lateral flow readout?
CLARIFIED ANSWER: FDA suggests using a pre-EUA to address nuances in trial design, such as considering patient and risk factors to incorporate broader mixed populations.
VERBATIM QUESTION: What nuances should be considered when evaluating a clinical trial design for nucleic acid tests with a lateral flow readout?
VERBATIM ANSWER: Yes I think a pre-EUA probably is the right method because there are, you know, I think nuances to this approach. You know you could also consider, you know, other patient factors, risk factors where folks may be exposed to kind of further mix populations. There's a number of ways to do this.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: clinical trial design, nucleic acid tests, lateral flow readout
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: Why is a pre-EUA process recommended for discussing clinical trial design approaches?
CLARIFIED ANSWER: FDA supports using a pre-EUA process for clinical trial design discussions due to the nuances of various approaches and the potential consideration of additional factors like patient and risk factors.
VERBATIM QUESTION: Why is a pre-EUA process recommended for discussing clinical trial design approaches?
VERBATIM ANSWER: Yes I think a pre-EUA probably is the right method because there are, you know, I think nuances to this approach. You know you could also consider, you know, other patient factors, risk factors where folks may be exposed to kind of further mix populations. There's a number of ways to do this.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: pre-EUA process, clinical trial design, patient and risk factors
REVIEW FLAG: False

QA Block 8-7
CLARIFIED QUESTION: What are acceptable methods to avoid bias in clinical trial designs involving app-based result interpretation?
CLARIFIED ANSWER: The FDA advises ensuring the use of a comparator method to directly enrich the study population and recommends consulting through a pre-EUA to address nuances like patient and risk factors that may influence bias.
VERBATIM QUESTION: What are acceptable methods to avoid bias in clinical trial designs involving app-based result interpretation?
VERBATIM ANSWER: Generally there are a variety of ways to enrich this clinical study. The proposal in this question generally appears acceptable. We would want to make sure that you are using the comparator method as the result that you're using to enrich your clinical study population. And if you have further questions or want to talk through the design you can reach out with a pre-EUA to discuss that study design as well. Yes I think a pre-EUA probably is the right method because there are, you know, I think nuances to this approach. You know you could also consider, you know, other patient factors, risk factors where folks may be exposed to kind of further mix populations. There's a number of ways to do this.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Bias prevention, Clinical trial design, Pre-EUA consultation
REVIEW FLAG: False


#### 9. Asymptomatic Claims for Multi-Analyte RT-PCR Tests

QA Block 9-1
CLARIFIED QUESTION: Is it acceptable for a multi-analyte RT-PCR test (SARS-CoV-2 and influenza AB) to have an asymptomatic claim for SARS-CoV-2 if the software can report only a SARS-CoV-2 result when ordered?
CLARIFIED ANSWER: The FDA currently does not have multi-analyte EUAs with asymptomatic claims. Insufficient data exists for asymptomatic influenza screening, but asymptomatic SARS-CoV-2 screening is supported. A multi-analyte test capable of reporting only SARS-CoV-2 results under certain conditions may be acceptable, subject to adequate controls and a proposed plan for review.
VERBATIM QUESTION: Is it acceptable for a multi-analyte RT-PCR test (SARS-CoV-2 and influenza AB) to have an asymptomatic claim for SARS-CoV-2 if the software can report only a SARS-CoV-2 result when ordered?
VERBATIM ANSWER: The questioner is correct that we do not currently have any multi-analyte EUAs that have an asymptomatic claim. At this point we don't have any - we don't have sufficient data supporting device performance or a public health need for an asymptomatic influenza screening claim. For SARS-CoV-2 we obviously know that there's many reports of asymptomatic infection and numerous studies that show detectable viral load in asymptomatic populations. So we have obviously granted asymptomatic screening claims for many SARS-CoV-2 tests at this point. So a test that's capable of reporting either a SARS-CoV-2 result alone or the multiplex result depending on the patient population that's being tested or the individuals' circumstances may be appropriate. We would want to see that there are sufficient controls to ensure that the user has the tools to report the appropriate results to the appropriate individual. So we would recommend that you submit a proposed plan and then we can discuss that further including, you know, what the labeling would look like and how the workflow would be handled there.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Multi-analyte RT-PCR tests, Asymptomatic claims, SARS-CoV-2 diagnostics
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: What constitutes sufficient controls to ensure users accurately report SARS-CoV-2 results for tests capable of multiplex results?
CLARIFIED ANSWER: FDA recommends submitting a proposed plan detailing sufficient controls to ensure users accurately report results, including labeling and workflow considerations.
VERBATIM QUESTION: What constitutes sufficient controls to ensure users accurately report SARS-CoV-2 results for tests capable of multiplex results?
VERBATIM ANSWER: We would want to see that there are sufficient controls to ensure that the user has the tools to report the appropriate results to the appropriate individual. So we would recommend that you submit a proposed plan and then we can discuss that further including, you know, what the labeling would look like and how the workflow would be handled there.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Multiplex testing controls, Accurate reporting, Proposed plans
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: How should developers propose a plan for review when seeking authorization for tests that may report single or multiple analyte results?
CLARIFIED ANSWER: The FDA recommends submitting a proposed plan for review of tests, ensuring sufficient controls for reporting appropriate results to the relevant individual. This can be discussed further, including details on labeling and workflow.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We would want to see that there are sufficient controls to ensure that the user has the tools to report the appropriate results to the appropriate individual. So we would recommend that you submit a proposed plan and then we can discuss that further including, you know, what the labeling would look like and how the workflow would be handled there.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: proposed plan for test review, asymptomatic claims, workflow and controls
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What specific details should be included in the labeling and workflow for multi-analyte tests with conditional reporting capabilities?
CLARIFIED ANSWER: The FDA recommends submitting a proposed plan for multi-analyte tests with conditional reporting capabilities to address labeling and workflow. The plan should ensure sufficient controls and tools for users to report the appropriate results to the correct individuals.
VERBATIM QUESTION: What specific details should be included in the labeling and workflow for multi-analyte tests with conditional reporting capabilities?
VERBATIM ANSWER: We would want to see that there are sufficient controls to ensure that the user has the tools to report the appropriate results to the appropriate individual. So we would recommend that you submit a proposed plan and then we can discuss that further including, you know, what the labeling would look like and how the workflow would be handled there.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Multi-analyte tests, Labeling, Workflow
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: Does the FDA require different validation for asymptomatic claims for influenza compared to SARS-CoV-2?
CLARIFIED ANSWER: The FDA currently does not have sufficient data to support asymptomatic claims for influenza screening, whereas for SARS-CoV-2, there is ample evidence of asymptomatic infections and detectable viral loads, which is why asymptomatic claims have been granted for SARS-CoV-2 tests.
VERBATIM QUESTION: Does the FDA require different validation for asymptomatic claims for influenza compared to SARS-CoV-2?
VERBATIM ANSWER: So the questioner is correct that we do not currently have any multi-analyte EUAs that have an asymptomatic claim. At this point we don't have any - we don't have sufficient data supporting device performance or a public health need for an asymptomatic influenza screening claim. For SARS-CoV-2 we obviously know that there's many reports of asymptomatic infection and numerous studies that show detectable viral load in asymptomatic populations. So we have obviously granted asymptomatic screening claims for many SARS-CoV-2 tests at this point.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Asymptomatic claims, SARS-CoV-2 diagnostics, Influenza diagnostics
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: Why are there currently no multi-analyte EUAs with an asymptomatic claim?
CLARIFIED ANSWER: There are currently no multi-analyte EUAs with asymptomatic claims because there is insufficient data on device performance or public health need for asymptomatic influenza screening. However, many asymptomatic screening claims have been granted for SARS-CoV-2 tests based on evidence of asymptomatic infections.
VERBATIM QUESTION: Why are there currently no multi-analyte EUAs with an asymptomatic claim?
VERBATIM ANSWER: So the questioner is correct that we do not currently have any multi-analyte EUAs that have an asymptomatic claim. At this point we don't have any - we don't have sufficient data supporting device performance or a public health need for an asymptomatic influenza screening claim. For SARS-CoV-2 we obviously know that there's many reports of asymptomatic infection and numerous studies that show detectable viral load in asymptomatic populations. So we have obviously granted asymptomatic screening claims for many SARS-CoV-2 tests at this point.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: multi-analyte EUAs, asymptomatic claims, influenza and SARS-CoV-2 testing
REVIEW FLAG: False


#### 10. Transitioning Respiratory Panels from EUA to 510k Approval

QA Block 10-1
CLARIFIED QUESTION: What are the criteria for determining if prospective clinical studies can be conducted on the instrument with the worst limit of detection in a 510k submission?
CLARIFIED ANSWER: FDA recommends that prospective studies use the instrument with the worst limit of detection only if data show comparable performance, precision, and reproducibility between instruments. Sponsors should submit a pre-submission for validation strategy review and refer to prior 510k decision summaries for similar pathogens.
VERBATIM QUESTION: What are the criteria for determining if prospective clinical studies can be conducted on the instrument with the worst limit of detection in a 510k submission?
VERBATIM ANSWER: This is something where we would generally want to have some further discussions about your approach. The proposal that you laid out might be acceptable. We would recommend providing data establishing that performance at low analyte levels, precision and reproducibility are similar between the instruments. And we would recommend that when you're pursuing the 510k pathway that you submit a pre-submission to discuss your proposed validation strategies and your comparative method for review. Right now there's quite a bit of information in previous 510k decision summaries of the flu and RSV. And we hope to get the decision summary for the BioFire Denovo posted fairly quickly. And so, since the studies that establish performance of the flu are likely to be similar to what we recommend for SARS-CoV-2, we would suggest that you take a look at those flu decision summaries together since what we would be looking for is there. And then since we do have limited resource capacity for pre-submissions right now, we recommend that you maximize the efficiency of that interaction by including specific questions that are targeted to your test and the remaining questions that you have after reviewing the publicly available information.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k submission, Limit of detection criteria, Pre-submission process
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: What data is necessary to demonstrate similar performance, precision, and reproducibility across multiple RT-PCR instruments for a 510k?
CLARIFIED ANSWER: The FDA recommends submitting data showing similar performance at low analyte levels, precision, and reproducibility across instruments. Pre-submissions should be made to discuss validation strategies and comparative methods for 510k reviews.
VERBATIM QUESTION: What data is necessary to demonstrate similar performance, precision, and reproducibility across multiple RT-PCR instruments for a 510k?
VERBATIM ANSWER: We would recommend providing data establishing that performance at low analyte levels. Precision and reproducibility are similar between the instruments. And we would recommend that when you're pursuing the 510k pathway that you submit a pre-submission to discuss your proposed validation strategies and your comparative method for review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k submission, RT-PCR performance data, validation requirements
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What topics should be covered in a pre-submission meeting when proposing validation strategies for transitioning from an EUA to a 510k?
CLARIFIED ANSWER: FDA recommends discussing validation strategies, comparative methods, and reviewing previous 510k decision summaries for similar viruses, like flu. Maximizing interaction efficiency by focusing on test-specific and remaining questions is advised.
VERBATIM QUESTION: What topics should be covered in a pre-submission meeting when proposing validation strategies for transitioning from an EUA to a 510k?
VERBATIM ANSWER: We would recommend that when you're pursuing the 510k pathway that you submit a pre-submission to discuss your proposed validation strategies and your comparative method for review. Right now there's quite a bit of information in previous 510k decision summaries of the flu and RSV. And we hope to get the decision summary for the BioFire Denovo posted fairly quickly. And so since the studies that establish performance of the flu are likely to be similar to what we recommend for SARS-CoV-2, we would suggest that you take a look at those flu decision summaries together since what we would be looking for is there. And then since we do have limited resource capacity for pre-submissions right now we recommend that you maximize the efficiency of that interaction by including specific questions that are targeted to your test and the remaining questions that you have after reviewing the publicly available information.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pre-submission meeting topics, EUA to 510k transition, Validation strategy
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: What are the key recommendations in the migration guidance for comparing two systems?
CLARIFIED ANSWER: The FDA mentions that the migration guidance provides recommendations for comparing two systems.
VERBATIM QUESTION: What are the key recommendations in the migration guidance for comparing two systems?
VERBATIM ANSWER: We also have, you know, the migration pathway. So I think that's got some good information - sorry migration guidance has some information about comparing, you know, two systems.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: migration guidance, system comparison, FDA recommendations
REVIEW FLAG: True

QA Block 10-5
CLARIFIED QUESTION: What prior 510k decision summaries should be reviewed to better understand FDA expectations for SARS-CoV-2 diagnostic tests?
CLARIFIED ANSWER: FDA recommends reviewing prior 510k decision summaries for flu and RSV, as these are likely similar to expectations for SARS-CoV-2 diagnostic tests. The BioFire Denovo decision summary will also be posted soon.
VERBATIM QUESTION: What prior 510k decision summaries should be reviewed to better understand FDA expectations for SARS-CoV-2 diagnostic tests?
VERBATIM ANSWER: Right now there's quite a bit of information in previous 510k decision summaries of the flu and RSV. And we hope to get the decision summary for the BioFire Denovo posted fairly quickly. And so since the studies that establish performance of the flu are likely to be similar to what we recommend for SARS-CoV-2, we would suggest that you take a look at those flu decision summaries together since what we would be looking for is there.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k decision summaries, SARS-CoV-2 diagnostics, Flu and RSV studies
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: How can developers ensure their pre-submission questions maximize efficiency given FDA's limited resource capacity?
CLARIFIED ANSWER: Developers should maximize the efficiency of pre-submission interactions by including specific, targeted questions about their test and addressing remaining questions after reviewing publicly available information.
VERBATIM QUESTION: How can developers ensure their pre-submission questions maximize efficiency given FDA's limited resource capacity?
VERBATIM ANSWER: And then since we do have limited resource capacity for pre-submissions right now we recommend that you maximize the efficiency of that interaction by including specific questions that are targeted to your test and the remaining questions that you have after reviewing the publicly available information.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pre-submission efficiency, FDA resource capacity, targeted questions
REVIEW FLAG: False


#### 11. Monitoring and Testing for SARS-CoV-2 Variants

QA Block 11-1
CLARIFIED QUESTION: What are the requirements for assessing whether predicted amino acid changes in viral proteins are critical to the test design?
CLARIFIED ANSWER: The template requires evaluating whether predicted amino acid changes in viral proteins are critical to test design and testing mutations or variants using available clinical or contrived specimens to assess their impact.
VERBATIM QUESTION: What are the requirements for assessing whether predicted amino acid changes in viral proteins are critical to the test design?
VERBATIM ANSWER: The template does state that for any viral mutations and variants that are identified as prevalent and/or clinically significant you should assess whether the resulting predicted amino acid changes in the viral proteins are critical to your test design. And if so we would ask that those mutations of variants should be evaluated using clinical specimens or contrived, you know, depending on availability to assess the impact of the mutation or variant on your test performance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: requirements for assessing viral protein changes, EUA template guidance, test design impact
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: How should mutations or variants be evaluated using clinical or contrived specimens if clinical specimens are not available?
CLARIFIED ANSWER: The FDA advises evaluating viral mutations and variants identified as prevalent or clinically significant using clinical specimens or contrived specimens if clinical specimens are unavailable. The assessment should determine the impact of predicted amino acid changes on test performance.
VERBATIM QUESTION: How should mutations or variants be evaluated using clinical or contrived specimens if clinical specimens are not available?
VERBATIM ANSWER: The template does state that for any viral mutations and variants that are identified as prevalent and/or clinically significant you should assess whether the resulting predicted amino acid changes in the viral proteins are critical to your test design. And if so we would ask that those mutations of variants should be evaluated using clinical specimens or contrived, you know, depending on availability to assess the impact of the mutation or variant on your test performance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: mutations and variants evaluation, clinical and contrived specimens, test design impact
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: What should be included in a plan for monitoring new and emerging SARS-CoV-2 variants?
CLARIFIED ANSWER: The EUA template requires a plan for monitoring and assessing the impact of new SARS-CoV-2 mutations and variants. It should include testing protocols, assessment of variant impacts on assay performance, and mitigation of risks associated with unknown variant impacts.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: The template does state that for any viral mutations and variants that are identified as prevalent and/or clinically significant you should assess whether the resulting predicted amino acid changes in the viral proteins are critical to your test design. And if so we would ask that those mutations of variants should be evaluated using clinical specimens or contrived, you know, depending on availability to assess the impact of the mutation or variant on your test performance. And then specifically the template suggests that you provide your plan for monitoring for new and emerging SARS-CoV-2 viral mutations and variants on an ongoing basis and for assessing the impact of mutations and variants that have been identified as prevalent and/or clinically significant on the performance of your assay over time. And this includes providing your plan that includes information on the potential impact of the initiations and variance on your test performance or explaining how the risk associated with the unknown performance of your device and samples from individuals with the variant can be adequately mitigative. So generally in the protocol that indicates how you would do that testing along with the other information requested in the template included to serve as that plan at the time of your EUA request. And, you know, as we do that with you we would discuss that protocol and plan with you as needed.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Monitoring SARS-CoV-2 variants, EUA template requirements, Test performance evaluation
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: How should test developers assess and document the potential impact of viral mutations on test performance over time?
CLARIFIED ANSWER: Test developers should assess the impact of prevalent or clinically significant viral mutations by evaluating whether amino acid changes affect test performance. They should document a plan for monitoring emerging mutations, testing affected variants, and mitigating associated risks, as outlined in the EUA template.
VERBATIM QUESTION: How should test developers assess and document the potential impact of viral mutations on test performance over time?
VERBATIM ANSWER: The template does state that for any viral mutations and variants that are identified as prevalent and/or clinically significant you should assess whether the resulting predicted amino acid changes in the viral proteins are critical to your test design. And if so we would ask that those mutations of variants should be evaluated using clinical specimens or contrived, you know, depending on availability to assess the impact of the mutation or variant on your test performance. And then specifically the template suggests that you provide your plan for monitoring for new and emerging SARS-CoV-2 viral mutations and variants on an ongoing basis and for assessing the impact of mutations and variants that have been identified as prevalent and/or clinically significant on the performance of your assay over time. And this includes providing your plan that includes information on the potential impact of the initiations and variance on your test performance or explaining how the risk associated with the unknown performance of your device and samples from individuals with the variant can be adequately mitigative. So generally in the protocol that indicates how you would do that testing along with the other information requested in the template included to serve as that plan at the time of your EUA request. And, you know, as we do that with you we would discuss that protocol and plan with you as needed.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Monitoring viral mutations, Assessing test performance, EUA documentation
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: What steps should be taken to mitigate risks associated with device performance on unknown variants?
CLARIFIED ANSWER: To mitigate risks associated with unknown variant performance, the FDA recommends evaluating critical amino acid changes in viral proteins, using clinical or contrived specimens as necessary, and developing a plan for monitoring variants. This plan should address the potential impacts of mutations and explain how risks from unknown performance will be mitigated.
VERBATIM QUESTION: What steps should be taken to mitigate risks associated with device performance on unknown variants?
VERBATIM ANSWER: The template does state that for any viral mutations and variants that are identified as prevalent and/or clinically significant you should assess whether the resulting predicted amino acid changes in the viral proteins are critical to your test design. And if so we would ask that those mutations of variants should be evaluated using clinical specimens or contrived, you know, depending on availability to assess the impact of the mutation or variant on your test performance. And then specifically the template suggests that you provide your plan for monitoring for new and emerging SARS-CoV-2 viral mutations and variants on an ongoing basis and for assessing the impact of mutations and variants that have been identified as prevalent and/or clinically significant on the performance of your assay over time. And this includes providing your plan that includes information on the potential impact of the mutations and variants on your test performance or explaining how the risk associated with the unknown performance of your device and samples from individuals with the variant can be adequately mitigated.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Mitigating risks from unknown variants, Device performance monitoring, EUA template requirements
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: What specific elements are required in a proposed protocol for testing the impact of variants, to be included in the EUA submission?
CLARIFIED ANSWER: The EUA template requires assessing whether prevalent or significant mutations affect your test design and evaluating these using clinical or contrived specimens. You must include a plan for ongoing monitoring of emerging variants, assess their impact on assay performance, and describe mitigation strategies for risks associated with unknown performance in variants.
VERBATIM QUESTION: What specific elements are required in a proposed protocol for testing the impact of variants, to be included in the EUA submission?
VERBATIM ANSWER: The template does state that for any viral mutations and variants that are identified as prevalent and/or clinically significant you should assess whether the resulting predicted amino acid changes in the viral proteins are critical to your test design. And if so we would ask that those mutations of variants should be evaluated using clinical specimens or contrived, you know, depending on availability to assess the impact of the mutation or variant on your test performance. And then specifically the template suggests that you provide your plan for monitoring for new and emerging SARS-CoV-2 viral mutations and variants on an ongoing basis and for assessing the impact of mutations and variants that have been identified as prevalent and/or clinically significant on the performance of your assay over time. And this includes providing your plan that includes information on the potential impact of the initiations and variance on your test performance or explaining how the risk associated with the unknown performance of your device and samples from individuals with the variant can be adequately mitigative. So generally in the protocol that indicates how you would do that testing along with the other information requested in the template included to serve as that plan at the time of your EUA request.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission requirements, Variant impact assessment, Protocol development
REVIEW FLAG: False


#### 12. Acceptability of International Data in U.S. Studies

QA Block 12-1
CLARIFIED QUESTION: Would having a clinical site in Canada along with other clinical sites in the U.S. be acceptable for the agency?
CLARIFIED ANSWER: FDA would assess the acceptability of including a Canadian site based on the volume of U.S. data and the study meeting U.S.-specific template criteria. Supplemental Canadian data can be submitted.
VERBATIM QUESTION: Would having a clinical site in Canada along with other clinical sites in the U.S. be acceptable for the agency?
VERBATIM ANSWER: I think that would probably depend on the volume of data that you have from the U.S. I think we would want to see the data specified in our template from the U.S. If you have supplemental data from Canada, you know, you could certainly submit that as well.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Canadian clinical sites, U.S. template criteria, Point of care studies
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: As long as we meet the minimum criteria specified in the template for data from the U.S., would it be acceptable to include additional data from Canada?
CLARIFIED ANSWER: As long as the data from the U.S. meet the minimum criteria specified in the template, supplemental data from Canada can be included.
VERBATIM QUESTION: As long as we meet the minimum criteria specified in the template for data from the U.S., would it be acceptable to include additional data from Canada?
VERBATIM ANSWER: I think that would probably depend on the volume of data that you have from the U.S. I think we would want to see the data specified in our template from the U.S. If you have supplemental data from Canada, you know, you could certainly submit that as well.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: U.S. and Canadian data inclusion, POC studies for SARS-CoV-2
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: Why does the FDA require point-of-care and at-home validation studies to be conducted in the U.S.?
CLARIFIED ANSWER: The FDA generally requires point-of-care and at-home validation studies to be conducted in the U.S. because of observed variations in these areas.
VERBATIM QUESTION: Why does the FDA require point-of-care and at-home validation studies to be conducted in the U.S.?
VERBATIM ANSWER: We do accept data from outside of the U.S. with the exception of generally for the point of care and at home validation studies we would want those to be done in the U.S. due to variations that we have seen particularly in those areas.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: point-of-care validation, at-home testing, FDA study requirements
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: What factors determine whether supplemental data from an international site can be submitted to the FDA?
CLARIFIED ANSWER: The FDA generally accepts international data with exceptions for point-of-care and at-home validation studies, which should be conducted in the U.S. Key considerations include the volume of U.S. data, adherence to FDA templates, and the comparability of international practices to U.S. standards.
VERBATIM QUESTION: What factors determine whether supplemental data from an international site can be submitted to the FDA?
VERBATIM ANSWER: We do accept data from outside of the U.S. with the exception of generally for the point of care and at home validation studies we would want those to be done in the U.S. due to variations that we have seen particularly in those areas. I think that would probably depend on the volume of data that you have from the U.S. I think we would want to see the data specified in our template from the U.S. If you have supplemental data from Canada, you know, you could certainly submit that as well. Yes I mean that's the safest bet right? I mean if you have international data from, you know, from POC sites then, you know, we start perhaps asking questions about well, you know, what exactly is the standard of practice at these POC sites, you know, so potentially, you know, you could make that argument that it's similar to the U.S. But, you know, if you can avoid having to make the argument, you know, that's just kind of one less thing that you have to justify to us.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: international data submission, point-of-care studies, FDA data requirements
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: What constitutes sufficient data volume from U.S. sites when supplementing with international data?
CLARIFIED ANSWER: The FDA requires sufficient data volume from U.S. sites to meet the criteria outlined in their template. Supplemental data from international sites, such as Canada, may be submitted but the focus should be on meeting U.S. requirements.
VERBATIM QUESTION: What constitutes sufficient data volume from U.S. sites when supplementing with international data?
VERBATIM ANSWER: I think that would probably depend on the volume of data that you have from the U.S. I think we would want to see the data specified in our template from the U.S. If you have supplemental data from Canada, you know, you could certainly submit that as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: U.S. data requirements, International data submission, Point-of-care study guidelines
REVIEW FLAG: False

QA Block 12-8
CLARIFIED QUESTION: How does the FDA assess the equivalence of standard practices at international point-of-care sites to U.S. standards?
CLARIFIED ANSWER: If international point-of-care site data is submitted, the FDA may question the site's standard practices and how they compare to U.S. practices. Avoiding this situation by adhering to U.S.-based data reduces the need for justification.
VERBATIM QUESTION: How does the FDA assess the equivalence of standard practices at international point-of-care sites to U.S. standards?
VERBATIM ANSWER: Yes I mean that's the safest bet right? I mean if you have international data from, you know, from POC sites then, you know, we start perhaps asking questions about well, you know, what exactly is the standard of practice at these POC sites, you know, so potentially, you know, you could make that argument that it's similar to the U.S. But, you know, if you can avoid having to make the argument, you know, that's just kind of one less thing that you have to justify to us.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: International data equivalence, Point-of-care site standards, U.S. vs. international standards
REVIEW FLAG: False

QA Block 12-9
CLARIFIED QUESTION: Is there any scenario where data from non-U.S. point-of-care sites might be accepted without additional justification?
CLARIFIED ANSWER: The FDA generally requires point-of-care and at-home validation studies to be conducted in the U.S. due to observed variations in those settings.
VERBATIM QUESTION: Is there any scenario where data from non-U.S. point-of-care sites might be accepted without additional justification?
VERBATIM ANSWER: We do accept data from outside of the U.S. with the exception of generally for the point of care and at home validation studies we would want those to be done in the U.S. due to variations that we have seen particularly in those areas.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Acceptance of non-U.S. data, Point-of-care studies
REVIEW FLAG: False


#### 13. Including Branding Information in EUA Submissions for Kits

QA Block 13-1
CLARIFIED QUESTION: Is it important to include product branding information in the EUA submission or can that be submitted post EUA?
CLARIFIED ANSWER: Product branding information can be included in the EUA submission, and labeling with branding is generally reviewed. Updates to branding, such as for distributors using different names, can be submitted post-authorization as a condition of the EUA.
VERBATIM QUESTION: And this question is about home collection kit EUA submission. Is it important to include product branding information in the EUA submission or can that be submitted post EUA?
VERBATIM ANSWER: So, you know, that may depend on exactly what you mean by product branding information. But generally we do review the labeling. And so that would probably include the product branding that you're referring to. We do usually include in the EUA a condition about adding labeling where, you know, for distributors that might distribute under a different name. And that's something that can be added after the initial authorization if you're looking to partner with different distributors. But the testing is included in the authorization and the, you know, name obviously would go on the labeling that we would review and authorize as part of the EUA.
SPEAKER QUESTION: Elizabeth Brunelli
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission, Product branding, Labeling requirements
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: Can distributors distribute a product under a different name after initial EUA authorization?
CLARIFIED ANSWER: FDA allows distributors to distribute products under a different name post-authorization if labeling is updated and authorized as part of the EUA.
VERBATIM QUESTION: Can distributors distribute a product under a different name after initial EUA authorization?
VERBATIM ANSWER: We do usually include in the EUA a condition about adding labeling where, you know, for distributors that might distribute under a different name. And that's something that can be added after the initial authorization if you're looking to partner with different distributors. But the testing is included in the authorization and the, you know, name obviously would go on the labeling that we would review and authorize as part of the EUA.
SPEAKER QUESTION: Elizabeth Brunelli
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: distribution under different name, EUA labeling
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: How does the FDA handle labeling updates for home collection kits submitted under a generic name?
CLARIFIED ANSWER: The FDA allows submission of home collection kits with a generic name initially. If the branding is later updated, a supplemental EUA request must be submitted for FDA review and authorization of the updated labeling.
VERBATIM QUESTION: How does the FDA handle labeling updates for home collection kits submitted under a generic name?
VERBATIM ANSWER: Okay. So you could submit it with the, you know, fairly generic name if that's what you're planning to use right now. And then if you decide to update it you would submit that update as a supplemental EUA request. And we would have to review and authorize that alternate labeling.
SPEAKER QUESTION: Elizabeth Brunelli
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: home collection kit labeling, EUA submission process
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: What is the process for submitting a supplemental EUA request to update branding information for an already authorized product?
CLARIFIED ANSWER: To update branding information for an already authorized product, you can initially submit with a generic name and later submit a supplemental EUA request to update the branding. The FDA will review and authorize the alternate labeling.
VERBATIM QUESTION: What is the process for submitting a supplemental EUA request to update branding information for an already authorized product?
VERBATIM ANSWER: Okay. So you could submit it with the, you know, fairly generic name if that's what you're planning to use right now. And then if you decide to update it you would submit that update as a supplemental EUA request. And we would have to review and authorize that alternate labeling.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Supplemental EUA process, Branding updates, Authorization requirements
REVIEW FLAG: False


#### 14. Guidance for Home Use Serology Antibody Test Development

QA Block 14-1
CLARIFIED QUESTION: Is it required to report results for a home use serology antibody test, similar to some of the antigen home use tests?
CLARIFIED ANSWER: FDA currently does not have specific recommendations for reporting results of home use serology antibody tests. Reporting can be coordinated through healthcare providers for prescription-use tests. FDA recommends a pre-EUA submission to discuss requirements for reporting.
VERBATIM QUESTION: Is it required to report results for a home use serology antibody test, similar to some of the antigen home use tests?
VERBATIM ANSWER: Okay. So this one is a little bit tricky. We don't have recommendations that we've put out yet for the home use serology antibody test. Generally if there is a healthcare provider involved which we would - which, you know, all of the serology tests that we have authorized so far are prescription use, we would - the coordination with the healthcare provider can be how the test results get reported. Otherwise we would, you know, discuss that further. And we would suggest a pre-submission or sorry a pre-EUA to discuss what we would want to see in that home use antibody test.
SPEAKER QUESTION: Anna Powell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: reporting requirements, home use serology antibody tests
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: Should vaccinated people be included in the performance study for a home use serology antibody test?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA with the proposal detailing reporting and inclusion of vaccinated individuals in the validation study for further discussion on this emerging area.
VERBATIM QUESTION: Should vaccinated people be included in the performance study for a home use serology antibody test?
VERBATIM ANSWER: And similarly with your question about including vaccinated people that, you know, is an area that, you know, is emerging now obviously as more and more people are becoming vaccinated. And so we would suggest that you submit a pre-EUA with your proposal both for reporting and for inclusion in your validation study so that we can discuss the specifics of your approach.
SPEAKER QUESTION: Anna Powell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: vaccinated individuals in study, serology antibody tests, pre-EUA recommendations
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: What is the response time for using the pre-EUA process to address protocols and questions for a home use serology test?
CLARIFIED ANSWER: The FDA evaluates priority based on public health needs and the number of submissions in-house but cannot provide a specific response timeline for pre-EUA requests.
VERBATIM QUESTION: So what is the response time if we use the pre-EUA to address the basics of protocol and the questions like this for the home use serology test? We heard that there's a very low priority for this particular test. Is that true?
VERBATIM ANSWER: So we would evaluate the priority of the request when it comes in in considering the public health needs at the time as well as the other submissions that we have in house. So I'm not able to give a specific timeline there.
SPEAKER QUESTION: Anna Powell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pre-EUA process, response timelines, test prioritization
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: Is it true that there is a very low priority for home use serology antibody tests?
CLARIFIED ANSWER: The FDA evaluates the priority of home use serology antibody tests based on public health needs and other submissions in-house but cannot provide a specific timeline.
VERBATIM QUESTION: Is it true that there is a very low priority for home use serology antibody tests?
VERBATIM ANSWER: So we would evaluate the priority of the request when it comes in in considering the public health needs at the time as well as the other submissions that we have in house. So I'm not able to give a specific timeline there.
SPEAKER QUESTION: Anna Powell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: home use serology tests, FDA priorities, response timelines
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: Does the FDA recommend coordination with a healthcare provider specifically for reporting test results in prescription-use serology tests?
CLARIFIED ANSWER: The FDA recommends coordination with a healthcare provider for reporting test results in prescription-use serology tests.
VERBATIM QUESTION: Does the FDA recommend coordination with a healthcare provider specifically for reporting test results in prescription-use serology tests?
VERBATIM ANSWER: Generally if there is a healthcare provider involved which we would - which, you know, all of the serology tests that we have authorized so far are prescription use, we would - the coordination with the healthcare provider can be how the test results get reported. Otherwise we would, you know, discuss that further.
SPEAKER QUESTION: Anna Powell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: reporting test results, prescription-use serology tests
REVIEW FLAG: False

QA Block 14-6
CLARIFIED QUESTION: What additional details would the FDA require in a pre-EUA submission for home use serology antibody tests?
CLARIFIED ANSWER: The FDA suggests submitting a pre-EUA to discuss details for home use serology antibody tests, covering reporting mechanisms and inclusion of vaccinated individuals in the validation study, as these areas are still emerging.
VERBATIM QUESTION: What additional details would the FDA require in a pre-EUA submission for home use serology antibody tests?
VERBATIM ANSWER: We don't have recommendations that we've put out yet for the home use serology antibody test. Generally if there is a healthcare provider involved which we would - which, you know, all of the serology tests that we have authorized so far are prescription use, we would - the coordination with the healthcare provider can be how the test results get reported. Otherwise we would, you know, discuss that further. And we would suggest a pre-submission or sorry a pre-EUA to discuss what we would want to see in that home use antibody test. And similarly with your question about including vaccinated people that, you know, is an area that, you know, is emerging now obviously as more and more people are becoming vaccinated. And so we would suggest that you submit a pre-EUA with your proposal both for reporting and for inclusion in your validation study so that we can discuss the specifics of your approach.
SPEAKER QUESTION: Anna Powell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pre-EUA details, home use serology tests, validation study
REVIEW FLAG: False

QA Block 14-7
CLARIFIED QUESTION: How should developers address the inclusion of vaccinated individuals in a validation study for new serology tests?
CLARIFIED ANSWER: FDA suggests submitting a pre-EUA with the proposal to address the inclusion of vaccinated individuals in a validation study, as this area is still emerging.
VERBATIM QUESTION: How should developers address the inclusion of vaccinated individuals in a validation study for new serology tests?
VERBATIM ANSWER: And similarly with your question about including vaccinated people that, you know, is an area that, you know, is emerging now obviously as more and more people are becoming vaccinated. And so we would suggest that you submit a pre-EUA with your proposal both for reporting and for inclusion in your validation study so that we can discuss the specifics of your approach.
SPEAKER QUESTION: Anna Powell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serology test validation, vaccinated individuals, pre-EUA submission
REVIEW FLAG: False

QA Block 14-8
CLARIFIED QUESTION: What criteria does the FDA use to determine the public health priority of pre-EUA submissions?
CLARIFIED ANSWER: The FDA evaluates the priority of pre-EUA requests based on current public health needs and other submissions already in-house.
VERBATIM QUESTION: What criteria does the FDA use to determine the public health priority of pre-EUA submissions?
VERBATIM ANSWER: So we would evaluate the priority of the request when it comes in in considering the public health needs at the time as well as the other submissions that we have in house. So I'm not able to give a specific timeline there.
SPEAKER QUESTION: Anna Powell
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pre-EUA priority, public health criteria, FDA process
REVIEW FLAG: False


#### 15. Clarifying Enrollment Period for Molecular Point of Care Templates

QA Block 15-1
CLARIFIED QUESTION: Is the two-week time period mentioned in the molecular point-of-care templates referring to 10 days or a full 14 days of prospective enrollment?
CLARIFIED ANSWER: Two weeks refers to 14 days, and the FDA emphasizes making a good faith effort to collect prospective samples for the study.
VERBATIM QUESTION: Is the two-week time period mentioned in the molecular point-of-care templates referring to 10 days or a full 14 days of prospective enrollment?
VERBATIM ANSWER: Yes, okay. Yes I mean two weeks is 14 days. So I mean that's the kind of, you know, the face value. You know the point there is that you've made some kind of good faith effort to collect some prospective samples to at least, you know, have that portion of it be kind of an all all comers kind of study. I mean that's very valuable information for us. So I would say, you know, just go with the 14 days.
SPEAKER QUESTION: Stacy Houseman
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: molecular point-of-care templates, prospective enrollment duration, data collection guidelines
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: Should the 14-day prospective enrollment period include only business days, which might extend the overall time frame to three weeks?
CLARIFIED ANSWER: FDA clarified that the two-week enrollment period means 14 calendar days, not restricted to business days, emphasizing good faith efforts to collect prospective samples.
VERBATIM QUESTION: Should the 14-day prospective enrollment period include only business days, which might extend the overall time frame to three weeks?
VERBATIM ANSWER: Yes, okay. Yes I mean two weeks is 14 days. So I mean that's the kind of, you know, the face value. You know the point there is that you've made some kind of good faith effort to collect some prospective samples to at least, you know, have that portion of it be kind of an all all comers kind of study. I mean that's very valuable information for us. So I would say, you know, just go with the 14 days.
SPEAKER QUESTION: Stacy Houseman
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: prospective enrollment period, 14 days vs. business days, molecular point of care templates
REVIEW FLAG: False


#### 16. Accessing FDA Guidance AB Priority List Online

QA Block 16-1
CLARIFIED QUESTION: Is there information on the FDA website regarding the transition plan from EUA to 510(k)?
CLARIFIED ANSWER: The FDA website contains a mention of the guidance document name related to the transition plan, which can be found on the guidance priority list.
VERBATIM QUESTION: Yes, hi, thank you for this opportunity. Toby did I hear correctly on that there may be some information on the Web site somewhere regarding the transition plan from EUA to 510k? Is there some general information out there?
VERBATIM ANSWER: I did mention something being on our Web site. It might be overstating it to call it information. The name of the guidance document is on our guidance priority list.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Transition plan from EUA to 510(k), FDA guidance priority list
REVIEW FLAG: False

QA Block 16-2
CLARIFIED QUESTION: Where can the guidance priority list be found?
CLARIFIED ANSWER: The guidance priority list can be found by Googling 'FDA guidance AB list,' and it should appear near the top.
VERBATIM QUESTION: Where can the guidance priority list be found?
VERBATIM ANSWER: If you Google, like, I think FDA guidance AB list it should come up pretty close to the top.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA guidance priority list, Accessing FDA documents
REVIEW FLAG: False

QA Block 16-3
CLARIFIED QUESTION: What is the FDA guidance AB list and how is it related to the guidance priority list?
CLARIFIED ANSWER: The FDA guidance AB list is a breakdown of the guidance priority list divided into an A list and a B list.
VERBATIM QUESTION: What is the FDA guidance AB list and how is it related to the guidance priority list?
VERBATIM ANSWER: We break the priority list down into an A list and a B list. And so we often refer to it as the AB list.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA guidance AB list, guidance priority list
REVIEW FLAG: False


#### 17. Validation Requirements for POC Testing and International Sites

QA Block 17-1
CLARIFIED QUESTION: Can the clinical study with the 30 positives and negatives for a point of care or at-home test be done outside of the U.S. if justification shows the sites are representative of U.S. sites?
CLARIFIED ANSWER: Clinical studies for diagnostic tests should either be conducted in the U.S. or have justification showing that the international sites and operators are representative of U.S. sites, such as CLIA settings.
VERBATIM QUESTION: Can the clinical study with the 30 positives and negatives for a point of care or at-home test be done outside of the U.S. if justification shows the sites are representative of U.S. sites?
VERBATIM ANSWER: Since the setting does impact the clinicals for those tests we do want to see that they are done either in the U.S. or that you're able to provide justification demonstrating that outside of the U.S. sites are representative of the U.S. sites where those would be done. So we would want to see that the operators are representative of, you know, operators in a U.S. CLIA setting for example for a point of care test.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical study location, point of care tests, international site justification
REVIEW FLAG: False

QA Block 17-2
CLARIFIED QUESTION: Is the clinical evaluation for a COVID-19 diagnostic test done by the operator or in a lab with clinical samples?
CLARIFIED ANSWER: The clinical evaluation needs to be performed in the intended setting of use for the test.
VERBATIM QUESTION: Is the clinical evaluation for a COVID-19 diagnostic test done by the operator or in a lab with clinical samples?
VERBATIM ANSWER: The clinical evaluation should be done in the setting in which the test should be used.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical evaluation, COVID-19 diagnostic tests, setting of use
REVIEW FLAG: False

QA Block 17-3
CLARIFIED QUESTION: How should the 30 positives and 30 negatives interact with samples tested in a CLIA waived setting for a point of care diagnostic test?
CLARIFIED ANSWER: The FDA recommends that validation for point-of-care tests involving 30 positives and 30 negatives should be performed with minimally trained operators, reflecting the real-world point-of-care use.
VERBATIM QUESTION: How should the 30 positives and 30 negatives interact with samples tested in a CLIA waived setting for a point of care diagnostic test?
VERBATIM ANSWER: I mean I think our opinion is that POC test is going to be run by folks that are minimally trained. And therefore we want to have the validation performed in a similar manner.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Point-of-care test validation, CLIA waived settings
REVIEW FLAG: False

QA Block 17-5
CLARIFIED QUESTION: What justification is required to demonstrate that international sites are representative of U.S. sites for clinical evaluation studies?
CLARIFIED ANSWER: The FDA requires justification showing that international sites are representative of U.S. sites, including having operators similar to those in U.S. CLIA settings for point-of-care tests.
VERBATIM QUESTION: What justification is required to demonstrate that international sites are representative of U.S. sites for clinical evaluation studies?
VERBATIM ANSWER: Since the setting does impact the clinicals for those tests we do want to see that they are done either in the U.S. or that you're able to provide justification demonstrating that outside of the U.S. sites are representative of the U.S. sites where those would be done. So we would want to see that the operators are representative of, you know, operators in a U.S. CLIA setting for example for a point of care test.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: international site justification, clinical evaluation, CLIA settings
REVIEW FLAG: False

QA Block 17-6
CLARIFIED QUESTION: For point-of-care tests, should validation studies involve operators who are representative of minimally trained users in CLIA-waived settings?
CLARIFIED ANSWER: FDA recommends that validation studies for point-of-care tests involve minimally trained users, as these are reflective of typical POC operators.
VERBATIM QUESTION: For point-of-care tests, should validation studies involve operators who are representative of minimally trained users in CLIA-waived settings?
VERBATIM ANSWER: I mean I think our opinion is that POC test is going to be run by folks that are minimally trained. And therefore we want to have the validation performedin a similar manner.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: POC test validation, Minimally trained operators, CLIA-waived settings
REVIEW FLAG: False

QA Block 17-7
CLARIFIED QUESTION: How should banked samples, including those collected internationally, be used in validation studies for point-of-care tests?
CLARIFIED ANSWER: Validation testing for point-of-care tests should ideally be done in the U.S., but if conducted internationally, the burden is on the submitter to justify that the procedures and practices are comparable to U.S. standards.
VERBATIM QUESTION: How should banked samples, including those collected internationally, be used in validation studies for point-of-care tests?
VERBATIM ANSWER: I think ideally all testing - validation testing for POC tests we would prefer it done in the U.S. Again, like, I mentioned before if it's done, you know, in an international site then the burden is on you to establish the procedures and practices using that site are, you know, are similar or identical to, you know, what would be done in the U.S.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Validation studies, International samples, Point-of-care tests
REVIEW FLAG: False

QA Block 17-8
CLARIFIED QUESTION: Is validation testing for point-of-care diagnostic tests required to reflect the intended use setting, including user training level and environmental conditions?
CLARIFIED ANSWER: The FDA expects validation testing for point-of-care tests to be conducted in a manner that reflects their intended use, including using minimally trained operators.
VERBATIM QUESTION: Is validation testing for point-of-care diagnostic tests required to reflect the intended use setting, including user training level and environmental conditions?
VERBATIM ANSWER: I mean I think our opinion is that POC test is going to be run by folks that are minimally trained. And therefore we want to have the validation performed in a similar manner.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: point-of-care tests, validation testing, user training
REVIEW FLAG: False

QA Block 17-9
CLARIFIED QUESTION: Does the inclusion of minimally trained operators align with the guidance on conducting the 30 positives and 30 negatives clinical study?
CLARIFIED ANSWER: FDA expects point-of-care tests to be validated by minimally trained operators to align with their intended use.
VERBATIM QUESTION: Does the inclusion of minimally trained operators align with the guidance on conducting the 30 positives and 30 negatives clinical study?
VERBATIM ANSWER: I mean I think our opinion is that POC test is going to be run by folks that are minimally trained. And therefore we want to have the validation performedin a similar manner.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: minimally trained operators, 30 positives and negatives study, point-of-care test validation
REVIEW FLAG: False

QA Block 17-10
CLARIFIED QUESTION: What specific procedures or practices must be demonstrated to show international sites reflect U.S. settings for point-of-care test validation?
CLARIFIED ANSWER: For validation testing of point-of-care (POC) tests conducted at international sites, the burden is on sponsors to demonstrate that the procedures and practices at those sites are similar or identical to those in U.S. settings.
VERBATIM QUESTION: What specific procedures or practices must be demonstrated to show international sites reflect U.S. settings for point-of-care test validation?
VERBATIM ANSWER: You know I think ideally all testing - validation testing for POC tests we would prefer it done in the U.S. Again, like, I mentioned before if it's done, you know, in an international site then the burden is on you to establish the procedures and practices using that site are, you know, are similar or identical to, you know, what would be done in the U.S.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Point-of-care (POC) test validation, Procedures for international site studies, Equivalence to U.S. settings
REVIEW FLAG: False


#### 18. Validation Requirements for High Throughput Testing Platforms

QA Block 18-1
CLARIFIED QUESTION: How extensive does the validation have to be if we want to include adding a high throughput platform to a multi-analyte molecular test?
CLARIFIED ANSWER: Certain aspects of validation are not expected to be repeated if not impacted. Validation for the high throughput platform, or justification showing representativeness, is required for impacted portions.
VERBATIM QUESTION: How extensive does the validation have to be if we want to include adding a high throughput platform to a multi-analyte molecular test?
VERBATIM ANSWER: Yes, and I think that there are certain aspects of validation that would not be impacted. And obviously we wouldn't expect to see those repeated. The portions that would be expected to be impacted we would want to see, you know, the validation with the high throughput platform or justification of why, you know, what you're able to demonstrate is representative.
SPEAKER QUESTION: Roxanne Chan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: High throughput platform validation, Molecular test requirements
REVIEW FLAG: False

QA Block 18-2
CLARIFIED QUESTION: Do we only need to perform work related to adding an extra instrument type, or do we have to repeat a whole set of validation, including analytical and clinical studies?
CLARIFIED ANSWER: The FDA does not expect repeated validation for aspects not impacted. However, validation is required for portions impacted by the high throughput platform, or justification should be provided if the results are representative.
VERBATIM QUESTION: Do we only need to perform work related to adding an extra instrument type, or do we have to repeat a whole set of validation, including analytical and clinical studies?
VERBATIM ANSWER: Yes, and I think that there are certain aspects of validation that would not be impacted. And obviously we wouldn't expect to see those repeated. The portions that would be expected to be impacted we would want to see, you know, the validation with the high throughput platform or justification of why, you know, what you're able to demonstrate is representative.
SPEAKER QUESTION: Roxanne Chan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: high throughput platform validation, analytical and clinical validation, multi-analyte test
REVIEW FLAG: False

QA Block 18-3
CLARIFIED QUESTION: Would it require more than bridging studies to validate the high throughput workflow for the test?
CLARIFIED ANSWER: Yes, the FDA anticipates that certain aspects of validation for the high throughput workflow would not need repetition, but for those impacted, validation or justification is required.
VERBATIM QUESTION: Would it require more than bridging studies to validate the high throughput workflow for the test?
VERBATIM ANSWER: Yes, and I think that there are certain aspects of validation that would not be impacted. And obviously we wouldn't expect to see those repeated. The portions that would be expected to be impacted we would want to see, you know, the validation with the high throughput platform or justification of why, you know, what you're able to demonstrate is representative.
SPEAKER QUESTION: Roxanne Chan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Validation for high throughput workflow, Bridging studies, Justification requirements
REVIEW FLAG: False

QA Block 18-4
CLARIFIED QUESTION: What should the validation package for the high throughput platform include, such as LOD, inclusivity, exclusivity, competition, coinfection, and clinical studies?
CLARIFIED ANSWER: The FDA states that certain validation aspects need not be repeated if unaffected, but impacted portions require validation with the high throughput platform or justification for their representativeness.
VERBATIM QUESTION: What should the validation package for the high throughput platform include, such as LOD, inclusivity, exclusivity, competition, coinfection, and clinical studies?
VERBATIM ANSWER: Yes, and I think that there are certain aspects of validation that would not be impacted. And obviously we wouldn't expect to see those repeated. The portions that would be expected to be impacted we would want to see, you know, the validation with the high throughput platform or justification of why, you know, what you're able to demonstrate is representative.
SPEAKER QUESTION: Roxanne Chan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: high throughput platform, validation requirements
REVIEW FLAG: False

### removed qa blocks
QA Block 2-1
CLARIFIED QUESTION: Does a test developer need to notify the FDA if they want to take their EUA off the market?
CLARIFIED ANSWER: FDA requests that test developers notify them via email if they intend to take their EUA off the market. FDA will revoke the EUA upon request and remove the test from the authorization list.
VERBATIM QUESTION: Does a test developer need to notify the FDA if they want to take their EUA off the market?
VERBATIM ANSWER: So we do ask the test developer to inform FDA if they intend to take their EUA off the market. You can do that just by sending in an email to the CDRH EUA template's mailbox and we will respond to you and go through the process with you that way. Generally if you're planning to take a test off the market we will revoke the EUA. And the revocation will note that it was per your request and we would remove the test developer from the EUA authorization list on our Web site.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA revocation, FDA notification, Authorization list update
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: What is the process to notify the FDA about taking an EUA off the market?
CLARIFIED ANSWER: Test developers should notify the FDA of their intent to take an EUA off the market by emailing the CDRH EUA template's mailbox. The FDA will revoke the EUA, noting it was voluntary, and remove the developer from the EUA authorization list.
VERBATIM QUESTION: What is the process to notify the FDA about taking an EUA off the market?
VERBATIM ANSWER: So we do ask the test developer to inform FDA if they intend to take their EUA off the market. You can do that just by sending in an email to the CDRH EUA template's mailbox and we will respond to you and go through the process with you that way. Generally if you're planning to take a test off the market we will revoke the EUA. And the revocation will note that it was per your request and we would remove the test developer from the EUA authorization list on our Web site.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA removal process, Developer notification, FDA revocation
REVIEW FLAG: False

QA Block 3-1
CLARIFIED QUESTION: What is the process to transition from EUAs to 510(k)s or De Novos for COVID-19 diagnostics?
CLARIFIED ANSWER: The FDA is working on a transition plan for devices offered under EUAs, included in the FY21 guidance priority list. EUAs remain in effect until the public health emergency ends, which usually does not happen quickly. The FDA has authorized a De Novo for BioFire, opening up the 510(k) pathway for similar SARS-CoV-2 tests. This process does not immediately impact other existing EUAs, and the FDA remains committed to reviewing EUAs as needed.
VERBATIM QUESTION: What is the process to transition from EUAs to 510(k)s or De Novos for COVID-19 diagnostics?
VERBATIM ANSWER: We have discussed this a little bit previously on calls. And we've mentioned before that I can't comment on a timeline specifically but we are working on a transition plan for devices that are offered under EUA. And this is included as a guidance document on the center's guidance priority list for FY21. If you take a look there you'll see the transition plan for medical devices distributed under enforcement policies or emergency's authorization during the COVID-19 public health emergency. Additionally it's important to recognize that generally unless they're revoked an EUA is in effect until the public health emergency is terminated. And the termination of a public health emergency does not typically happen on a particularly accelerated timeline. You can see that there are previous public health emergencies, like, Zika and Ebola that still have not been terminated. Now we have authorized the first test for marketing beyond the public health emergency with the BioFire Denovo. And that does open up the 510k pathway for other molecular diagnostic SARS-CoV-2 tests both individual or a single analyte SARS-CoV-2 test as well as multi-analyte panels which the Bio Fire test is. But that Denovo does not impact any other EUAs other than the BioFire EUA for that same identical test which was revoked concurrent to granting the Denovo. BioFire's other EUAs and other developer's EUAs were not impacted.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Transition from EUA to 510(k)/De Novo, COVID-19 diagnostic regulations, Public health emergency timelines
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: How does the BioFire De Novo authorization impact EUAs for its other tests besides the identical one?
CLARIFIED ANSWER: The BioFire De Novo authorization only impacted the EUA for the identical test, which was revoked when the De Novo was granted. Other EUAs, including those from BioFire and other developers, were not affected.
VERBATIM QUESTION: How does the BioFire De Novo authorization impact EUAs for its other tests besides the identical one?
VERBATIM ANSWER: But that Denovo does not impact any other EUAs other than the BioFire EUA for that same identical test which was revoked concurrent to granting the Denovo. BioFire's other EUAs and other developer's EUAs were not impacted.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: BioFire De Novo authorization, Impact on EUAs, EUA revocation
REVIEW FLAG: False

QA Block 6-1
CLARIFIED QUESTION: Is there any indication on review priorities for SARS-CoV-2 pre-submissions?
CLARIFIED ANSWER: The FDA continues to review SARS-CoV-2 pre-submissions during the pandemic, prioritizing reviews based on public health needs and specifics of the device.
VERBATIM QUESTION: Is there any indication on review priorities for SARS-CoV-2 pre-submissions?
VERBATIM ANSWER: We have obviously seen delays in CDRH on pre-submission and 510k reviews during the pandemic. So this question is asking whether that applies - if a pre-sub is submitted for a SARS-CoV-2 assay that does not currently have an EUA authorization. So generally we are broadly committed to ensuring that the public has access to a wide variety of test options for COVID-19 and we do intend to continue to review SARS-CoV-2 pre-submissions to address public health needs. So to some extent - so COVID-19 related pre-submissions are one of the categories of pre-submissions that we do continue to review. And the review of those would be prioritized based on the public health needs. So we would still consider the particulars about the device in question as to whether it would be a priority with you.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SARS-CoV-2 pre-submissions, Review priorities, FDA review process
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: Should a test designed for home use be validated for home use?
CLARIFIED ANSWER: The FDA generally requires tests designed for home use to be validated for that specific purpose.
VERBATIM QUESTION: Should a test designed for home use be validated for home use?
VERBATIM ANSWER: And, you know, in this case if it is a test that is designed for home use we would generally want to see that it is validated for home use.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: home use tests, validation requirements, FDA review process
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: If we had data in the U.S. but also included a site in Canada, would that be acceptable?
CLARIFIED ANSWER: FDA states that the inclusion of Canadian data depends on sufficient data from the U.S., meeting template requirements. Supplemental data from Canada can be submitted.
VERBATIM QUESTION: If we had data in the U.S. but also included a site in Canada, would that be acceptable?
VERBATIM ANSWER: I think that would probably depend on the volume of data that you have from the U.S. I think we would want to see the data specified in our template from the U.S. If you have supplemental data from Canada, you know, you could certainly submit that as well.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Canadian data usage, U.S. data requirements, Supplemental data submission
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: What is the FDA's stance on point-of-care validation studies conducted outside of the U.S.?
CLARIFIED ANSWER: FDA generally requires point-of-care and at-home validation studies to be conducted in the U.S. due to observed variations in these areas.
VERBATIM QUESTION: What is the FDA's stance on point-of-care validation studies conducted outside of the U.S.?
VERBATIM ANSWER: We do accept data from outside of the U.S. with the exception of generally for the point of care and at home validation studies we would want those to be done in the U.S. due to variations that we have seen particularly in those areas.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: point-of-care validation studies, international data requirements
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: What does the FDA mean by "product branding information" in the context of EUA submissions?
CLARIFIED ANSWER: The FDA generally reviews labeling as part of the EUA process, which includes product branding. Labeling changes, such as using a different distributor name, can be added post-authorization through a supplemental EUA request.
VERBATIM QUESTION: What does the FDA mean by "product branding information" in the context of EUA submissions?
VERBATIM ANSWER: That may depend on exactly what you mean by product branding information. But generally we do review the labeling. And so that would probably include the product branding that you're referring to. We do usually include in the EUA a condition about adding labeling where, you know, for distributors that might distribute under a different name. And that's something that can be added after the initial authorization if you're looking to partner with different distributors. But the testing is included in the authorization and the, you know, name obviously would go on the labeling that we would review and authorize as part of the EUA.
SPEAKER QUESTION: Elizabeth Brunelli
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submissions, product branding, labeling requirements
REVIEW FLAG: False

QA Block 16-4
CLARIFIED QUESTION: Why does the FDA split its guidance priority list into an A list and a B list?
CLARIFIED ANSWER: The FDA splits the priority list into an A list and a B list for easier reference, which is commonly referred to as the AB list.
VERBATIM QUESTION: Why does the FDA split its guidance priority list into an A list and a B list?
VERBATIM ANSWER: Yes. We break the priority list down into an A list and a B list. And so we often refer to it as the AB list.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA guidance priority list, A and B list structure
REVIEW FLAG: False

QA Block 16-5
CLARIFIED QUESTION: What does the FDA recommend for locating the guidance AB list online?
CLARIFIED ANSWER: The FDA recommends Googling 'FDA guidance AB list' to locate it online.
VERBATIM QUESTION: What does the FDA recommend for locating the guidance AB list online?
VERBATIM ANSWER: If you Google, like, I think FDA guidance AB list it should come up pretty close to the top.
SPEAKER QUESTION: Elaine Allan
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA guidance priority list, online search tips, AB list
REVIEW FLAG: False

QA Block 17-4
CLARIFIED QUESTION: Can the clinical evaluation involving 30 positives and 30 negatives for a diagnostic test be conducted abroad if procedures and practices are shown to be similar to U.S. sites?
CLARIFIED ANSWER: Validation testing for point-of-care tests should ideally be performed in the U.S. If conducted abroad, evidence must be provided to confirm that the procedures and practices align with U.S. standards.
VERBATIM QUESTION: Can the clinical evaluation involving 30 positives and 30 negatives for a diagnostic test be conducted abroad if procedures and practices are shown to be similar to U.S. sites?
VERBATIM ANSWER: You know I think ideally all testing - validation testing for POC tests we would prefer it done in the U.S. Again, like, I mentioned before if it's done, you know, in an international site then the burden is on you to establish the procedures and practices using that site are, you know, are similar or identical to, you know, what would be done in the U.S.
SPEAKER QUESTION: Ella Holston
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Validation testing location, Point-of-care tests, Standards for international testing
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-03 12:14:29 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 18
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What distinguishes over-the-counter COVID-19 tests from those requiring a prescription?
QI 1-2: What defines a reissue of a letter of authorization versus a revised EUA under the FDA's procedures?
QI 1-3: Under what circumstances does the FDA issue granting letters for EUAs?
QI 1-4: What types of changes to test labeling require FDA concurrence?
QI 1-5: How does the FDA categorize updates to EUAs that involve minor changes, such as fixing typos?
QI 1-6: What is the significance of adding reference panel result data to the test labeling according to the FDA?

#### Section 2 of 18
##### Explicit Questions Extraction
QE 2-1: Does a test developer need to notify the FDA if they want to take their EUA off the market?
QE 2-2: Would a test developer be removed from the EUA page if they notify FDA about taking their EUA off the market?

##### Implicit Questions Extraction
QI 2-1: What is the process to notify the FDA about taking an EUA off the market?
QI 2-2: What happens to the test listing on the EUA website if a developer voluntarily stops marketing their test?
QI 2-3: Will the FAA notate on the removed list whether the withdrawal of a test was voluntary?
QI 2-4: Is there a specific email or mailbox to notify FDA about stopping marketing a test?

#### Section 3 of 18
##### Explicit Questions Extraction
QE 3-1: What is the process to transition from EUAs to 510(k)s or De Novos for COVID-19 diagnostics?
QE 3-2: What is the timeline for transitioning from EUAs to 510(k)s or De Novos for COVID-19 diagnostics?

##### Implicit Questions Extraction
QI 3-1: Where can developers access the guidance document that outlines the transition plan for devices under EUA?
QI 3-2: What are the implications of the BioFire De Novo authorization for developers of other SARS-CoV-2 tests?
QI 3-3: Does the authorization of a De Novo test affect EUAs for molecular diagnostic tests by other developers?
QI 3-4: How does the BioFire De Novo authorization impact EUAs for its other tests besides the identical one?
QI 3-5: What is the FDA's approach to managing EUAs as the public health emergency continues indefinitely?
QI 3-6: Does the FDA plan to stop reviewing EUAs based solely on timeline considerations?
QI 3-7: Can developers still submit EUAs for COVID-19 diagnostic tests despite ongoing transition planning?

#### Section 4 of 18
##### Explicit Questions Extraction
QE 4-1: Would the FDA accept an EUA request with a general description of the process for shipping and specimen handling, leaving specific logistics to be established by each laboratory or by the collection kit manufacturer?
QE 4-2: Can an at-home test be performed in a public setting such as a college, school, or workplace instead of strictly in a home?
QE 4-3: If an at-home test is performed in a public setting by the facility rather than the individual, are such tests exempt from CLIA regulations?

##### Implicit Questions Extraction
QI 4-1: What specific details should be included in an accessioning protocol for a home collection kit to support an EUA submission?
QI 4-2: What level of consistency is expected across multiple laboratories using the same home collection kit, particularly in terms of using identical instructions?
QI 4-3: How should developers ensure that purchasers of collection kits are using the correct assay associated with the kit?
QI 4-4: What are the FDA's expectations regarding minor edits to home collection kit labeling made for specific programs?
QI 4-5: What assurances are needed to confirm that sample shipping and stability are adequately addressed in an EUA request for a home collection kit?
QI 4-6: In what scenarios would a CLIA waiver be required for a facility using an at-home test?

#### Section 5 of 18
##### Explicit Questions Extraction
QE 5-1: Can multi-analyte antigen tests leverage contrived samples for the initial authorization with a closed authorization commitment?
QE 5-2: What are the validation requirements for multi-analyte antigen tests if the sample types used do not survive the archival process?
QE 5-3: What steps should be taken if technological considerations preclude the use of archived specimens for multi-analyte antigen tests?

##### Implicit Questions Extraction
QI 5-1: What is the FDA's expectation for a comparator test when conducting a prospective study for a multi-analyte antigen test?
QI 5-2: What alternative approaches are acceptable if archived specimens cannot be used for validation due to technological limitations?
QI 5-3: Is a pre-EUA necessary to address specific technological issues with sample stability for validation?

#### Section 6 of 18
##### Explicit Questions Extraction
QE 6-1: Is there any indication on review priorities for SARS-CoV-2 pre-submissions?
QE 6-2: Does the prioritization for pre-submissions extend to a SARS-CoV-2 assay without an existing EUA authorization?

##### Implicit Questions Extraction
QI 6-1: What factors does the FDA consider when determining the priority of reviewing SARS-CoV-2 related pre-submissions?
QI 6-2: Does the FDA intend to continue reviewing SARS-CoV-2 pre-submissions despite delays in other review categories?
QI 6-3: Are there specific criteria for prioritizing COVID-19 related pre-submissions based on public health needs?

#### Section 7 of 18
##### Explicit Questions Extraction
QE 7-1: Do you continue to review submissions for professional use rapid antigen tests with point of care settings with a CLIA certificate of waiver?
QE 7-2: Would submissions without data for self-testing in a home use setting be considered low priority?
QE 7-3: Should a test designed for home use be validated for home use?
QE 7-4: Are you still reviewing point of care tests?

##### Implicit Questions Extraction
QI 7-1: What factors does the FDA consider when deciding EUA review priorities for COVID-19 tests?
QI 7-2: Will tests that reduce reliance on limited test supplies or increase throughput receive higher prioritization?
QI 7-3: Does the FDA require tests intended for home use to be validated in that specific setting?
QI 7-4: How does the intended use of a test affect FDA's review prioritization?
QI 7-5: Can developers discuss the specific prioritization decisions regarding their test directly with the FDA?

#### Section 8 of 18
##### Explicit Questions Extraction
QE 8-1: Is it acceptable to recruit asymptomatic subjects with recent positive test results if an equal number of asymptomatic subjects with recent negative test results are also recruited for a clinical trial design to enrich for asymptomatic positives for a nucleic acid test with a lateral flow readout?
QE 8-2: Should a clinical trial design for a nucleic acid test use a comparator method as the result for enriching the clinical study population?
QE 8-3: Can further questions regarding the clinical trial design be addressed through a pre-EUA request?

##### Implicit Questions Extraction
QI 8-1: What other patient factors or risk factors could be considered to further mix populations in a clinical trial to enrich for asymptomatic positives?
QI 8-2: What nuances should be considered when evaluating a clinical trial design for nucleic acid tests with a lateral flow readout?
QI 8-3: Why is a pre-EUA process recommended for discussing clinical trial design approaches?
QI 8-4: What are acceptable methods to avoid bias in clinical trial designs involving app-based result interpretation?

#### Section 9 of 18
##### Explicit Questions Extraction
QE 9-1: Is it acceptable for a multi-analyte RT-PCR test (SARS-CoV-2 and influenza AB) to have an asymptomatic claim for SARS-CoV-2 if the software can report only a SARS-CoV-2 result when ordered?

##### Implicit Questions Extraction
QI 9-1: What constitutes sufficient controls to ensure users accurately report SARS-CoV-2 results for tests capable of multiplex results?
QI 9-2: How should developers propose a plan for review when seeking authorization for tests that may report single or multiple analyte results?
QI 9-3: What specific details should be included in the labeling and workflow for multi-analyte tests with conditional reporting capabilities?
QI 9-4: Does the FDA require different validation for asymptomatic claims for influenza compared to SARS-CoV-2?
QI 9-5: Why are there currently no multi-analyte EUAs with an asymptomatic claim?

#### Section 10 of 18
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 10-1: What are the criteria for determining if prospective clinical studies can be conducted on the instrument with the worst limit of detection in a 510k submission?
QI 10-2: What data is necessary to demonstrate similar performance, precision, and reproducibility across multiple RT-PCR instruments for a 510k?
QI 10-3: What topics should be covered in a pre-submission meeting when proposing validation strategies for transitioning from an EUA to a 510k?
QI 10-4: What are the key recommendations in the migration guidance for comparing two systems?
QI 10-5: What prior 510k decision summaries should be reviewed to better understand FDA expectations for SARS-CoV-2 diagnostic tests?
QI 10-6: How can developers ensure their pre-submission questions maximize efficiency given FDA's limited resource capacity?

#### Section 11 of 18
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 11-1: What are the requirements for assessing whether predicted amino acid changes in viral proteins are critical to the test design?
QI 11-2: How should mutations or variants be evaluated using clinical or contrived specimens if clinical specimens are not available?
QI 11-3: What should be included in a plan for monitoring new and emerging SARS-CoV-2 variants?
QI 11-4: How should test developers assess and document the potential impact of viral mutations on test performance over time?
QI 11-5: What steps should be taken to mitigate risks associated with device performance on unknown variants?
QI 11-6: What specific elements are required in a proposed protocol for testing the impact of variants, to be included in the EUA submission?

#### Section 12 of 18
##### Explicit Questions Extraction
QE 12-1: Would having a clinical site in Canada along with other clinical sites in the U.S. be acceptable for the agency?
QE 12-2: If we had data in the U.S. but also included a site in Canada, would that be acceptable?
QE 12-3: As long as we meet the minimum criteria specified in the template for data from the U.S., would it be acceptable to include additional data from Canada?

##### Implicit Questions Extraction
QI 12-1: What is the FDA's stance on point-of-care validation studies conducted outside of the U.S.?
QI 12-2: Why does the FDA require point-of-care and at-home validation studies to be conducted in the U.S.?
QI 12-3: What factors determine whether supplemental data from an international site can be submitted to the FDA?
QI 12-4: What constitutes sufficient data volume from U.S. sites when supplementing with international data?
QI 12-5: How does the FDA assess the equivalence of standard practices at international point-of-care sites to U.S. standards?
QI 12-6: Is there any scenario where data from non-U.S. point-of-care sites might be accepted without additional justification?

#### Section 13 of 18
##### Explicit Questions Extraction
QE 13-1: Is it important to include product branding information in the EUA submission or can that be submitted post EUA?

##### Implicit Questions Extraction
QI 13-1: What does the FDA mean by "product branding information" in the context of EUA submissions?
QI 13-2: Can distributors distribute a product under a different name after initial EUA authorization?
QI 13-3: How does the FDA handle labeling updates for home collection kits submitted under a generic name?
QI 13-4: What is the process for submitting a supplemental EUA request to update branding information for an already authorized product?

#### Section 14 of 18
##### Explicit Questions Extraction
QE 14-1: Is it required to report results for a home use serology antibody test, similar to some of the antigen home use tests?
QE 14-2: Should vaccinated people be included in the performance study for a home use serology antibody test?
QE 14-3: What is the response time for using the pre-EUA process to address protocols and questions for a home use serology test?
QE 14-4: Is it true that there is a very low priority for home use serology antibody tests?

##### Implicit Questions Extraction
QI 14-1: Does the FDA recommend coordination with a healthcare provider specifically for reporting test results in prescription-use serology tests?
QI 14-2: What additional details would the FDA require in a pre-EUA submission for home use serology antibody tests?
QI 14-3: How should developers address the inclusion of vaccinated individuals in a validation study for new serology tests?
QI 14-4: What criteria does the FDA use to determine the public health priority of pre-EUA submissions?

#### Section 15 of 18
##### Explicit Questions Extraction
QE 15-1: Is the two-week time period mentioned in the molecular point-of-care templates referring to 10 days or a full 14 days of prospective enrollment?
QE 15-2: Should the 14-day prospective enrollment period include only business days, which might extend the overall time frame to three weeks?

##### Implicit Questions Extraction

#### Section 16 of 18
##### Explicit Questions Extraction
QE 16-1: Is there information on the FDA website regarding the transition plan from EUA to 510(k)?
QE 16-2: Where can the guidance priority list be found?

##### Implicit Questions Extraction
QI 16-1: What is the FDA guidance AB list and how is it related to the guidance priority list?
QI 16-2: Why does the FDA split its guidance priority list into an A list and a B list?
QI 16-3: What does the FDA recommend for locating the guidance AB list online?

#### Section 17 of 18
##### Explicit Questions Extraction
QE 17-1: Can the clinical study with the 30 positives and negatives for a point of care or at-home test be done outside of the U.S. if justification shows the sites are representative of U.S. sites?
QE 17-2: Is the clinical evaluation for a COVID-19 diagnostic test done by the operator or in a lab with clinical samples?
QE 17-3: How should the 30 positives and 30 negatives interact with samples tested in a CLIA waived setting for a point of care diagnostic test?
QE 17-4: Can the clinical evaluation involving 30 positives and 30 negatives for a diagnostic test be conducted abroad if procedures and practices are shown to be similar to U.S. sites?

##### Implicit Questions Extraction
QI 17-1: What justification is required to demonstrate that international sites are representative of U.S. sites for clinical evaluation studies?
QI 17-2: For point-of-care tests, should validation studies involve operators who are representative of minimally trained users in CLIA-waived settings?
QI 17-3: How should banked samples, including those collected internationally, be used in validation studies for point-of-care tests?
QI 17-4: Is validation testing for point-of-care diagnostic tests required to reflect the intended use setting, including user training level and environmental conditions?
QI 17-5: Does the inclusion of minimally trained operators align with the guidance on conducting the 30 positives and 30 negatives clinical study?
QI 17-6: What specific procedures or practices must be demonstrated to show international sites reflect U.S. settings for point-of-care test validation?

#### Section 18 of 18
##### Explicit Questions Extraction
QE 18-1: How extensive does the validation have to be if we want to include adding a high throughput platform to a multi-analyte molecular test?
QE 18-2: Do we only need to perform work related to adding an extra instrument type, or do we have to repeat a whole set of validation, including analytical and clinical studies?
QE 18-3: Would it require more than bridging studies to validate the high throughput workflow for the test?
QE 18-4: What should the validation package for the high throughput platform include, such as LOD, inclusivity, exclusivity, competition, coinfection, and clinical studies?

##### Implicit Questions Extraction
